Chinese Medical Injections for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Network Meta-analysis

Haiyin Hu^{1,*}
Zhaochen Ji^{1,*}
Xiaoyu Qiang¹
Shigang Liu²
Xiaodi Sheng¹
Zhe Chen¹
Fanqi Liu³
Hui Wang¹
Junhua Zhang¹

¹Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China; ²Department of Respiratory Diseases, Guang'anmen Hospital, Beijing, People's Republic of China; ³Department of Cardiovascular Disease, The Second Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, People's Republic of China

*These authors contributed equally to this work

Background: The World Health Organization has indicated that chronic obstructive pulmonary disease (COPD) may become the third leading cause of death by 2030. Acute exacerbation of COPD (AECOPD) is an important process in clinical treatment. Recent studies have shown that Chinese medical injections (CMI) are effective against AECOPD, but the effective difference among different CMIs remains unclear. The aim of this network meta-analysis (NMA) is to compare the therapeutic effect of various CMIs.

Methods: We conducted an overall, systematic literature search in the China National Knowledge Infrastructure, Wanfang, VIP, SinoMed, PubMed, Embase, Cochrane Library, and Web of Science databases to retrieve randomized controlled trials (RCTs) of CMIs for AECOPD published up to January 2021. The Cochrane risk of bias tool was used to assess the risk of bias. Stata 13.1 and WinBUGS 14.3 were used for data analyses.

Results: In total, 103 RCTs involving 8767 participants and 23 CMIs were included. The results indicated that among all treatments conventional Western medical therapy (WM) plus Dengzhanxixin injection (DZXX) led to the best improvement in the clinical efficacy and the ratio of forced expiratory volume in one second (FEV₁) to forced vital capacity (FVC) (FEV₁/FVC), with surface under the cumulative ranking curve (SUCRA)=80.47% and 98.55%, respectively. Moreover, Shenmai injection (SM) plus WM and Reduning injection (RDN) plus WM led to the best improvement in the FEV₁ (SUCRA=80.18%) and the ratio of forced expiratory volume in one second to the predicted value (FEV₁%, SUCRA=87.28%). Shengmai injection (SGM) plus WM led to the most considerable shortening in the length of hospital stay (SUCRA=94.70%). Cluster analysis revealed that WM+DZXX had the most favorable response for clinical efficacy and FEV₁, as well as clinical efficacy and FEV₁/FVC, WM+RDN had the most favorable response for clinical efficacy and FEV₁%, WM+SGM had the most favorable response for clinical efficacy and length of hospital stay.

Conclusion: WM+DZXX, WM+RDN, and WM+SGM were noted to be the optimum treatment regimens for improving in clinical efficacy, FEV₁, FEV₁/FVC, FEV₁% and reducing the hospital stay length of AECOPD patients. Considering the limitations this NMA may have, the current results warrant further verification via additional high-quality studies.

Keywords: traditional Chinese medicine, TCM, Chinese medical injection, CMI, acute exacerbation of chronic obstructive pulmonary disease, AECOPD, COPD, network meta-analysis, NMA

Introduction

Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by progressive, persistent airflow restriction and abnormal airway inflammation. When

Correspondence: Hui Wang, Junhua Zhang
Email wanghui1983@foxmail.com;
zjhtcm@foxmail.com

Received: 30 August 2021
Accepted: 14 November 2021
Published: 17 December 2021

International Journal of Chronic Obstructive Pulmonary Disease 2021:16 3363–3386

3363

© 2021 Hu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

the related respiratory symptoms worsen continually, warranting conventional medication changes, the condition is defined as acute exacerbation of COPD (AECOPD).^{1–3} AECOPD can severely impact the patient's daily life and impair their lung function.⁴ According to the World Health Organization, the COPD is expected to be the third leading cause of death by 2030 globally.^{5–8} In the Asia-Pacific region, COPD incidence is estimated to be as high as 6.2% and rising.⁹ In 2019 an expert consensus on anti-infective therapy for AECOPD in China showed that COPD prevalence in Chinese residents aged >40 and >60 years was 13.7% and >27.0%.^{10–12} Mortality risk increases significantly in patients with AECOPD.¹³

Corticosteroids and long-acting bronchodilators are recommended as the first-line therapies for AECOPD along with the additional use of antibiotics if required.¹⁴ However, long-term treatment with systemic corticosteroids is immunosuppressive, which increases the risk and severity of viral infections.¹⁵ Moreover, the wide application of antibiotics has led to bacterial resistance.¹⁶ These factors can reduce treatment efficacy further.¹⁷

Chinese medical injections (CMIs) are widely used in clinical practices.¹⁶ Some clinical trials have evaluated the efficacy of CMIs for patients with AECOPD and reported their effectiveness in inhibiting inflammation, regulating immune function, and alleviating symptoms.^{18–20}

Recent systematic reviews have also shown that CMIs are effective for treating AECOPD,^{21–25} but the effective difference among different CMIs remains unclear. Therefore, in this study, we performed a network meta-analysis (NMA) of all published RCTs on CMIs for treating of AECOPD to compare the therapeutic effect of the different CMIs used.

Methods

Protocol and Registration

The study protocol was registered on PROSPERO (Registration No. CRD42021236247; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236247).

Eligibility Criteria

Inclusion Criteria

We included RCTs with participants diagnosed with AECOPD (based on diagnosis and treatment guidance of chronic obstructive pulmonary disease).²⁶ The experimental group received a CMI plus conventional Western

medical therapy (WM) (including oxygen inhalation, spasmolysis, anti-asthmatic and nutritional support, and antibiotic treatment), whereas the control group received WM alone or another CMI plus WM. No restrictions on language, sex, age, and disease course were imposed.

The main outcome was clinical efficacy and the evaluation criteria were as follows:

- Significantly effective: clinical symptoms and signs such as cough and dyspnea disappeared or improved significantly, the pulmonary rales disappeared or decreased, and laboratory examinations showed normal results at the end of the treatment.
- Effective: clinical symptoms, signs, and laboratory examinations, all improved at the end of the treatment.
- Invalid: the condition neither improved nor worsened by the end of the treatment.

Next, clinical efficacy rate was calculated as [(significantly effective cases+effective cases)/total cases]×100%.

The secondary outcomes were as follows:

- Lung function: this included forced expiratory volume in one second (FEV₁), the ratio of FEV₁ to the predicted value (FEV₁%), and the ratio of FEV₁ to forced vital capacity (FEV₁/FVC), as recommended by the Global Strategy for Prevention, Diagnosis and Management of COPD.¹⁴
- Length of hospital stay: this is closely related to the cost of hospitalization and the economic burden of patients.²⁷

The improvements in the lung function and length of hospital stay were expressed as means ± standard deviations.

Exclusion Criteria

We excluded studies including AECOPD patients with other comorbidities such as gastroesophageal reflux disease, depression, and osteoporosis—all of which are associated with COPD exacerbation and COPD development acceleration.²⁸ We also excluded studies where a combination of multiple TCM injections was used, or where TCM injections were combined with other therapies (decoction, acupuncture, moxibustion, etc). Finally, conference articles, duplicated literature, unavailable studies, and studies with missing data were all excluded.

Data Sources and Search Strategy

Eight databases including the China National Knowledge Infrastructure, Wanfang, VIP, SinoMed, PubMed, Embase, Cochrane Library, and Web of Science were searched for eligible studies published from database inception until January 27, 2021. We used search terms including Chinese medicine, injection, COPD, and chronic obstructive pulmonary disease, etc. The complete search strategy is provided in [Supplementary File.1](#). For example, we used the following search strategy on PubMed:

```
#1(((((((Pulmonary Disease; Chronic Obstructive
[MeSH Terms]) OR (Asthma-Chronic Obstructive
Pulmonary Disease Overlap Syndrome[MeSH Terms]))
OR (COPD; Severe Early-Onset[Supplementary
Concept])) OR (pulmonary disease; chronic obstructive
[Title/Abstract])) OR (chronic obstructive pulmonary dis-
ease[Title/Abstract])) OR (chronic airflow obstruction
[Title/Abstract])) OR (COPD[Title/Abstract])) OR
(chronic obstructive lung disease[Title/Abstract])) OR
(chronic obstructive airway disease[Title/Abstract]))
```

```
#2((((Traditional Chinese medicine[MeSH Terms]) OR
(Traditional Chinese medicine[Text Word])) OR (Chinese
medicine[Text Word])) OR (injection[Text Word])) OR
(zhongyi[Text Word])) OR (zhongyao[Text Word]))
```

```
#3((randomized trials[MeSH Terms]) OR (randomized
trials[Text Word])) OR (randomized[Text Word]))
```

```
#4#1 AND #2 AND #3
```

Literature Selection and Data Extraction

Two researchers independently conducted literature screening and data extraction. Eligible studies were reviewed and the following data were abstracted using a pre-established data extraction table: age, sex, sample size, intervention/control measures, treatment course, outcomes, and adverse reactions. The selected studies and extracted data were cross-checked by two authors and if there were any disagreements they were resolved through consulting with a third party.

Quality Assessment

The quality of the included studies was evaluated using the Cochrane risk of bias tool recommended by the Cochrane Handbook for Systematic Reviews Version 5.3. Study quality was evaluated on the basis of seven aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases.²⁹ For each item the use of the right

method was rated as low risk of bias, unclear description was rated as unknown risk of bias, and the use of an incorrect method was rated as high risk of bias. All results were cross-checked by two authors and if there were any disagreements they were resolved through consulting with a third party.

Statistical Analysis

Dichotomous outcomes were measured as odds ratios (ORs), whereas continuous outcomes were measured as mean differences (MDs). When 95% confidence interval (CI) of the ORs and MDs did not contain 1 and 0, respectively, the differences were considered statistically significant.

Stata 13.1 was used to draw a network plot—where thicker lines indicated a higher number of the RCTs and a larger dot indicated a larger sample size. An inconsistency test was specifically needed when a closed loop formed in network plot. An inconsistency test was used to mainly evaluate the degree of consistency between the direct comparison results and indirect comparison results. Here $P \geq 0.05$ indicated low inconsistency in the closed loop, whereas $P < 0.05$ indicated significant inconsistency.

We used the Markov Chain Monte Carlo method with a random-effect model on WinBUGS 14.3 to perform Bayesian NMA. The iterations were set to 400,000. The first 100,000 times were used for annealing to eliminate the influence of the initial value and the last 300,000 times were used for sampling. The results are reported as the ORs and MDs with their respective 95% CIs. Surface under the cumulative ranking curve (SUCRA) was used to rank the efficacy of each intervention. The publication bias was assessed by comparison-adjusted funnel plot with Begg's test. Cluster analysis was conducted using STATA 13.1 to determine the dependency between outcomes and thus to the best interventions. This study was reported in accordance with PRISMA extension for network meta-analysis.³⁰

Results

Literature Search and Characteristics of the Included Studies

After our preliminary literature search 2430 studies were obtained of which 345 duplicates were removed. A total of 1653 articles were excluded after reading titles and abstracts because they were non-RCTs, non-AECOPD studies, concomitant use of other therapies, included

patients with other diseases, animal studies, or systematic reviews. Furthermore, 329 studies were excluded after reading full texts because they reported unrelated outcomes, incomplete data, or lack of full text. Finally, 103

RCTs were included. PRISMA flow diagram for study selection is shown in Figure 1.

The characteristics of included studies are shown in Table 1. One hundred and three RCTs comprised a total of

Figure 1 PRISMA flow diagram.

Notes: PRISMA figure adapted from Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med.* 2015;162(11):777–784. Creative Commons.³⁰

Table 1 The Characteristics of Included Studies

Study	Sample size		Gender		Age (years)		Interventions		Courses (days)	Outcomes
	T1 (T2)	C	Male	Female	T1 (T2)	C	T1 (T2)	C		
Cai Lili 2014 ⁵⁷	55	55	69	41	75±4.8	74±5.4	WM+KA	WM	14	②⑤⑪⑫
Chen Weizhong 2014 ⁵⁸	77	77	89	65	64.7±12.2	65.8±11.8	WM+RDN	WM	7	②③⑤⑪⑫
Chen Zhuo 2013 ⁵⁹	52	48	60	40	66.6±7.4	63.8±7.8	WM+DH	WM	14	②
Chi Yongsheng 2015 ⁶⁰	48	48	42	54	76.45±5.66	77.68±6.21	WM+SF	WM	14	②⑤
Cui Yandong 2010 ⁶¹	24	24	31	17	50-74	51-76	WM+CKZ	WM	14	②
Dong Hongzhen 2015 ⁶²	30	30	39	21	62.3±1.9	61.3±2.1	WM+RDN	WM	7	②
Du Jin 2014 ⁶³	30	30	34	26	65±8.4	62±9.8	WM+DH	WM	14	②⑧
Du Yong 2015 ⁶⁴	60	60	82	38	67.54±10.66	66.38±11.34	WM+TRQ	WM	10	②
Duan Limin 2015 ⁶⁵	46	46	63	29	70.3±5.8	70.3±5.8	WM+XBJ	WM	7	②
Fan Yongxia 2011 ⁶⁶	25	25	29	21	58	57	WM+DH	WM	14	②
Feng Qing 2015 ⁶⁷	33	32	38	27	62±5.0	64±6.0	WM+TRQ	WM	7	②
Feng Zhijun 2010 ⁶⁸	54	52	67	39	64.5±6.8	64.5±6.8	WM+TRQ	WM	-	②
Fu Dongwei 2012 ⁶⁹	35	35	41	29	61.45±5.23	59.57±5.84	WM+TRQ	WM	15	②
Fu Qin 2009 ⁷⁰	50	50	92	8	80-93	81-94	WM+TRQ	WM	7-10	②
Fu Yongwang 2009 ⁷¹	65	63	68	60	61.2±1.2	61.8±2.8	WM+TRQ	WM	10	②⑤
Ge Zhongkai 2015 ⁷²	30	30	39	21	53.1±8.5	52.6±8.2	WM+TRQ	WM	10	②③⑪
Ge Zhongkai 2016 ⁷³	32	32	41	23	54.9±4.4	55.7±4.6	WM+DH	WM	14	②
Guo Xia 2009 ⁷⁴	35	35	40	30	67	66	WM+SM	WM	15	②
Han Fang 2015 ⁷⁵	62	60	70	52	56	61	WM+XYP	WM	14	③⑤⑫
Hao Tianpao 2010 ⁷⁶	30	30	42	18	66±6	67±5	WM+XBJ	WM	10	②
He Shaoling 2019 ⁷⁷	44	44	60	28	57.97±7.56	58.31±6.86	WM+XBJ	WM	14	②⑪⑫
He Xiang 2016 ⁷⁸	35	35	56	14	69.39±7.56	70.24±6.89	WM+TRQ	WM	7	②⑤
He Yongliang 2012 ⁷⁹	40	42	58	24	63.4±10.3	62.8±10.5	WM+DS	WM	10-14	②
Hu Xiaolin 2016 ⁸⁰	50(50)	50	115	35	69.3±6.3(66.7±4.2)	68.4±5.8	WM+XBJ(WM+TRQ)	WM	7	②③⑥
Hua Wenshan 2014 ⁸¹	20	20	21	19	55-80	50-75	WM+TRQ	WM	-	②
Huang Bin 2006 ⁸²	30	30	45	15	64.21±8.21	64.21±8.21	WM+TRQ	WM	14	②③⑤
Kang Jin 2016 ⁸³	60	60	69	51	44.37±13.25	45.36±14.85	WM+TRQ	WM	7	②
Li Daxiang 2015 ⁸⁴	33	33	33	33	53.1±1.3	55.8±7.7	WM+XBJ	WM	3	②⑤
Li Guoling 2009 ⁸⁵	36	36	53	19	72.25±9.340	71.50±9.637	WM+TRQ	WM	-	②④
Li Linlin 2014 ⁸⁶	38	38	42	34	64.3±3.2	66.3±3.8	WM+TRQ	WM	7	②④
Li Wen 2010 ⁸⁷	28	26	35	19	67.1±7.1	67.8±8.2	WM+TRQ	WM	10	①②
Liang Gang 2009 ⁸⁸	30	30	41	19	81.2±6.8	80.1±6.5	WM+DS	WM	14	②⑤
Liang Wei 2017 ⁸⁹	35	35	45	25	62.34±5.52	61.76±5.59	WM+TRQ	WM	7	②
Liao Wensheng 2008 ⁹⁰	30	28	39	19	68.3±7.4	65.2±5.9	WM+SF	WM	14	②⑪⑫

(Continued)

Table 1 (Continued).

Study	Sample size		Gender		Age (years)		Interventions		Courses (days)	Outcomes
	TI (T2)	C	Male	Female	TI (T2)	C	TI (T2)	C		
Ling Daobo 2009 ⁹¹	30	30	44	16	71.5	70.8	WM+XBj	WM	7	(2,8)
Liu Hongbo 2008 ⁹²	60	60	79	41	64.24±12.35	63.55±11.35	WM+TRQ	WM	14	(2,3,5,7,12)
Liu Honghong 2016 ⁹³	30	30	33	27	69.00±5.73	68.10±5.94	WM+XYP	WM	–	(2,4,11,12)
Liu Yan 2019 ⁹⁴	30	30	32	28	60.53±8.42	63.71±9.52	WM+SXT	WM	14	(2,3,5,11,12)
Liu Zhanxiang 2007 ⁹⁵	100	98	103	95	61.2±1.2	61.8±2.8	WM+TRQ	WM	7	(2)
Liu Zhonggui 2014 ⁹⁶	56	54	65	45	63.1±2.5	63.1±2.5	WM+TRQ	WM	10	(2,3,11)
Long Hai 2012 ⁹⁷	64	60	88	36	61.10±7.21	61.12±12.35	WM+TRQ	WM	7	(2,3,5,11)
Lu Na 2013 ⁹⁸	49	49	71	27	72.2	71.5	WM+TRQ	WM	14	(2,7)
Mu Lin 2014 ⁹⁹	36	36	43	29	51~82	51~82	WM+XBj	WM	7	(2,5)
Pang Lijian 2015 ¹⁰⁰	55	55	51	59	55±4.25	54±3.65	WM+RDN	WM	14	(2,5)
Peng Bo 2007 ¹⁰¹	30	30	35	25	60.3±6.6	59.3±8.18	WM+TRQ	WM	12	(2,12)
Qiu Qin 2013 ¹⁰²	35	35	48	22	72.4±11.3	72.4±11.3	WM+XBj	WM	10	(2,8,11,12)
Qu Qiu2014 ¹⁰³	30	30	44	16	78±5.7	78±5.7	WM+HJT	WM	10	(2,5)
Ren Yuejuan 2013 ¹⁰⁴	35	35	41	29	62.5±5.4	62.8±5.01	WM+SF	WM	14	(2,5)
Shi Ce 2009 ¹⁰⁵	25	25	37	13	45~75	46~77	WM+TRQ	WM	7~14	(2)
Shi Daihui 2013 ¹⁰⁶	42	42	54	30	55~84	56~82	WM+TRQ	WM	10	(2,5)
Shi Yiying 2009 ¹⁰⁷	23	23	27	19	58	57	WM+DH	WM	14	(2,11,12)
Song Liang 2012 ¹⁰⁸	40	40	58	22	52~82	54~84	WM+CKZ	WM	7	(2)
Sun Jin 2008 ¹⁰⁹	75	63	–	–	–	–	WM+TRQ	WM	14	(2,7)
Tang Na 2016 ¹¹⁰	60	60	87	33	62.8±9.6	63.1±9.5	WM+TRQ	WM	–	(2,3,4,11)
Tang Wei 2012 ¹¹¹	56	56	65	47	72.5±5.0	71.0±4.2	WM+HQ	WM	21	(2)
Tian Rukang 2009 ¹¹²	38	34	40	32	68	66	WM+SM	WM	15	(2,5)
Tian Tulie 2015 ¹¹³	37	37	42	32	60.8	59.7	WM+RDN	WM	10	(2,11,12)
Wang Aidong 2011 ¹¹⁴	72	70	100	42	61.8±6.3	64.7±8.6	WM+TRQ	WM	10~14	(2,5,11,12)
Wang Haiyan 2010 ¹¹⁵	30	30	41	19	64	62	WM+DZXX	WM	10	(2,3,11)
Wang Lixia 2008 ¹¹⁶	50	46	59	37	68.5	67.2	WM+TRQ	WM	7~14	(2)
Wang Qiu 2013 ¹¹⁷	47	47	67	27	60.4	60.4	WM+TRQ	WM	10	(2,7)
Wang Tiejun 2012 ¹¹⁸	39	40	50	29	55.76±7.23	56.36±7.69	WM+SXN	WM	14	(3,6)
Wang Tongbing 2015 ¹¹⁹	46	46	53	39	59.26±2.68	59.26±2.68	WM+TRQ	WM	14	(2,3,5,11)
Wang Xianghua 2011 ¹²⁰	39	39	46	32	62.7±4.8	58.8±6.1	WM+TRQ	WM	14	(2,3,5,11)
Wang Xueqin 2015 ¹²¹	30	30	29	31	69.6	71.0	WM+XBj	WM	7	(2)
Wang Yong 2007 ¹²²	32	28	51	9	69.5±7.8	69.3±8.0	WM+SGM	WM	14	(2,4,5,6,7)
Wei Sizun 2011 ¹²³	40	40	44	36	59.28±8.56	58.08±9.28	WM+TRQ	WM	–	(2,3,11)
Wei Yaomin 2014 ¹²⁴	37	33	39	31	61.3±2.5	61.3±2.5	WM+RDN	WM	10	(2,3,11)
Wnag Yuanjun 2012 ¹²⁵	50	50	69	31	40~65	40~65	WM+XBj	WM	7	(2)

Wu Beishou 2015 ¹²⁶	38	38	39	37	50.7±9.3	53.6±6.8	WM+Salvianolate	WM	14	②
Wu Dengxiang 2015 ¹²⁷	50	50	56	44	52.5±5.7	53.4±6.7	WM+TRQ	WM	15	②⑤
Wu Yi 2017 ¹²⁸	40	40	52	28	66±6	67±5	WM+CKZ	WM	7	②
Xia Chunxia 2010 ¹²⁹	40	40	58	22	69.9±11.3	69.1±10.9	WM+KDZ	WM	14	②⑤
Xiang Wei 2012 ¹³⁰	44	42	43	43	32.5±2.3	39.85±1.73	WM+CKZ	WM	7	②
Xiang Zhi 2020 ¹³¹	60	60	68	52	68.01±10.28	67.25±9.4	WM+TRQ	WM	10	④⑤⑫
Xiao Chenxi 2018 ¹³²	45	44	53	36	68.14±9.41	67.15±8.62	WM+HQ	WM	14	②④⑨⑩
Xie Yonghong 2005 ¹³³	52	30	49	33	63.67±8.21	63.41±9.35	WM+TRQ	WM	15	②⑤⑦
Xiong Suqiong 2013 ¹³⁴	56	56	63	49	66.7	66.5	WM+HQ	WM	14	②
Xu Weijun 2017 ¹³⁵	32	36	44	24	73.60±10.60	75.00±8.30	WM+TRQ	WM	14	②⑤⑪⑫
Yang Jiwei 2012 ¹³⁶	110	110	149	71	56.60±6.20	56.60±6.20	WM+DH	WM	14	②⑪⑫
Yang Ruifang 2010 ¹³⁷	42	40	63	19	66.5±5.8	67.2±4.6	WM+DH	WM	14	②
Yang Weizhong 2014 ¹³⁸	60	60	78	42	70.0±6.4	70.0±6.4	WM+TRQ	WM	7	②④
Yang Xiuhong 2006 ¹³⁹	14	12	16	10	62.8±11.2	62.8±11.2	WM+TRQ	WM	10	②
Ye Ling 2010 ¹⁴⁰	30	27	50	7	—	—	WM+XBJ	WM	10	②⑤⑧⑪⑫
YE Shihua 2016 ¹⁴¹	40	40	45	35	62.4±3.4	62.4±3.9	WM+RDN	WM	35	②⑪⑫
Yin Libo 2009 ¹⁴²	32	30	44	18	73.38±7.61	74±10.47	WM+TRQ	WM	10	②⑤
YU Changxiu 2020 ¹⁴³	42	42	56	28	56.5±2.3	57.5±2.1	WM+SM	WM	14	②③
Zhang Chimei 2014 ¹⁴⁴	30	28	35	23	65.1±5.4	63.8±5.1	WM+HQ	WM	14	②
Zhang Li 2013 ¹⁴⁵	60	60	56	64	70.6±3.3	70.6±3.3	WM+DH	WM	14	②
Zhang Liyun 2017 ¹⁴⁶	30	30	51	9	64.51±11.31	65.04±12.42	WM+ZCL	WM	7	②
Zhang Qiang 2015 ¹⁴⁷	30	30	42	18	66.5±8	64.8±10	WM+QKL	WM	14	②⑪
Zhang Qiong 2014 ¹⁴⁸	64	64	71	57	64.45±9.46	64.41±9.45	WM+DH	WM	14	②
Zhang Wenqian 2010 ¹⁴⁹	36	36	49	23	60.4	61.5	WM+QKL	WM	7	②⑤
Zhang Xiaohua 2016 ¹⁵⁰	47	47	75	19	50–82	53–75	WM+HH	WM	15	②
Zhang Xin 2014 ¹⁵¹	46	46	62	30	67.8±7.4	67.6±7.2	WM+XYP	WM	14	②③⑪
Zhang Ying 2004 ¹⁵²	29	29	38	20	71.48±7.72	69.34±7.83	WM+TRQ	WM	12	①②⑥⑦
Zhang Yuanhua 2015 ¹⁵³	35	35	45	25	65	66	WM+KDZ	WM	10	②
Zhao Zhenhuan 2016 ¹⁵⁴	50	50	74	26	64.8±6.9	68.3±7.8	WM+SHL	WM	10	②
Zhang Yali 2017 ¹⁵⁵	45	44	57	32	65.9±13.4	66.4±12.8	WM+SF	WM	14	②⑤⑪⑫
Zhou Aizhu 2013 ¹⁵⁶	20	20	35	5	62±4.5	62±4.5	WM+XST	WM	14	②⑤⑪⑫
Zhou Jianguo 2014 ¹⁵⁷	30	30	32	28	72.6±5.4	73.1±5.8	WM+RDN	WM	7	①②
Zhou Zhong 2009 ¹⁵⁸	72	50	83	39	63.67±7.25	65.27±9.35	WM+TRQ	WM	10–14	②⑤
Zuo Xiqing 2010 ¹⁵⁹	30	30	48	12	70.35±5.12	70.85±4.04	WM+DH	WM	14	②⑤

Notes: ① Chinese Medical Symptom Scores; ② Clinical efficacy; ③ FEV₁; ④ Length of hospital stay; ⑤ Blood gas analysis; ⑥ Blood routine examination; ⑦ Sign; ⑧ Blood coagulation function; ⑨ Immunologic function; ⑩ Mechanical ventilation index; ⑪ FEV₁/FVC; ⑫ FEV₁ %.

Abbreviations: TI, treatment group 1; T2, treatment group 2; C, control group; WM, conventional Western medical therapy; CKZ, Chuankezhi injection; DH, Danhong injection; DS, Danshen injection; DZXX, Dengzhanxin injection; HH, Honghua injection; HJT, Hongjingtian injection; HQ, Huangqi injection; KA, Kangai injection; KDZ, Kudiezi injection; QKL, Qingkailing injection; RDN, Reduning injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; SHL, Shuanghuanglian injection; SXN, Shuxuetong injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanning injection; XBJ, Xuebijing injection; XST, Xuesaitong injection; ZCL, Zhichuanling injection; Salvianolate, Salvianolate injection.

8767 patients, including 4461 and 4306 participants in the treatment group and control group, respectively. The sample size of these studies ranged from 26 to 220. The number of male and female patients was 5502 and 3127, respectively. However, one study did not report the sex ratio. The participant's ages ranged from 30 to 94 years. All included studies were conducted in China and among them one was a three-arm RCT and 102 were two-arm RCTs.

In total 23 CMIs were included: Chuankezhi injection (CKZ), Danhong injection (DH), Danshen injection (DS), Dengzhanxin injection (DZXX), Honghua injection (HH), Hongjingtian injection (HJT), Huangqi injection (HQ), Kangai injection (KA), Kudiezi injection (KDZ), Qingkailing injection (QKL), Reduning injection (RDN), Shenfu injection (SF), Shengmai injection (SGM), Shenmai injection (SM), Shuanghuanglian injection (SHL), Shuxuening injection (SXN), Shuxuetong injection (SXT), Tanreqing injection (TRQ), Xiyanping injection (XYP), Xuebijing injection (XBJ), Xuesaitong injection (XST), Zhichuanling injection (ZCL), and Salvianolate injection (Salvianolate). Details about the included CMIs are given in [Supplementary Table S1](#). The treatment duration ranged from 3 to 35 days.

Risk of Bias

The assessment of risk of bias for all the included studies is illustrated in [Figure 2](#) and [Supplementary Table S2](#).

Regarding random sequence generation, 32 studies used the correct stochastic grouping method and thus

were assessed to have low risk, whereas two studies grouped with registration order and thus were assessed to have high risk. The remaining 69 studies reported “random allocation” without specific methods and were assessed to have unclear risk.

Regarding allocation concealment, 102 studies were assessed to have unclear risk because they did not describe their allocation methods. Moreover, one study allotted drugs with a specially assigned person and was assessed to have low risk.

Regarding blinding of participants and personnel, only three studies concealed the used interventions from patients, and thus, these studies were assessed to have low risk. The other 100 studies were assessed to have unclear risk.

Regarding blinding of outcome assessment, 42 studies did not describe the blinding of outcome assessment, but all results assessed using objective indicators, thus, these studies were assessed to have low risk. However, 16 studies used subjective indicators alone to assess result and thus were assessed to have high risk. The remaining studies were deemed to have unclear risk.

Regarding incomplete outcome data, the outcome data of all the included studies were complete, and thus, these studies were assessed to have low risk.

Regarding selective reporting, one study was assessed to have high risk due to the inconformity between its methods and results. The other studies did not report selectively and were assessed to have low risk.

Figure 2 Assessment of the risk of bias.

All the included studies were deemed to have unclear risk of other bias because some details in these studies (eg, conflict of interest and registration scheme) were unclear.

Bayesian NMA Results

Clinical Efficacy

In total, 99 studies evaluated clinical efficacy, included 22 CMIs and 8326 patients. There are 98 two-arm and one three-arm RCTs, included 23 direct and 230 indirect comparisons. The network plot is presented in [Figure 3A](#).

One closed loop formed in the network plot, and it required an inconsistency test of the direct and indirect comparisons in this closed loop. The results indicated that the inconsistent probability between direct and indirect comparisons in the closed loop WM–(WM+TRQ)–(WM+XBJ) was low (ROR=2.261, 95%CI: 1.00, 6.65, $P=0.139$, [Supplementary Figure S1](#) and [Figure S2](#)).

The clinical efficacy of WM+CKZ (OR=5.37, 95%CI: 1.93, 12.25), WM+DH (OR=6.34, 95%CI: 3.02, 11.96), WM+DS (OR=6.89, 95%CI: 1.33, 22.74), WM+DZXX (OR=115.4, 95%CI: 1.42, 514), WM+KDZ (OR=6.88, 95%CI: 1.18, 24.15), WM+QKL (OR=5.86, 95%CI: 1.04, 20.03), WM+RDN (OR=4.65, 95%CI: 2.11, 9.08), WM+SF (OR=4.87, 95%CI: 1.59, 11.89), WM+SM (OR=4.51, 95%CI: 1.14, 12.99), WM+TRQ (OR=4.48,

95%CI: 3.28, 6.02), and WM+XBJ (OR=3.52, 95%CI: 1.91, 6.1) was significantly higher than that of WM alone. Other comparisons did not show significant differences. The detailed results are shown in [Table 2](#).

WM+DZXX was ranked the best in clinical efficacy (SUCRA=80.47%), followed by WM+DH (SUCRA=66.78%) and WM+HJT (SUCRA=65.66%). All SUCRA rankings for clinical efficacy are presented in [Supplementary Table S3](#).

FEV₁

In total, 18 RCTs using eight of the CMIs reported FEV₁ improvements in AECOPD patients. The 18 RCTs (one three-arm and 17 two-arm) included 1715 patients. In total, 9 direct and 27 indirect comparisons formed. The network plot is presented in [Figure 3B](#).

In the network plot of the included comparisons that reported FEV₁, one closed loop needed an inconsistency test. The direct and indirect comparisons of closed loop WM–(WM+TRQ)–(WM+XBJ) were consistent (ROR=1.004, 95%CI: 1.00, 2.38, $P=0.993$, [Supplementary Figure S3](#) and [Figure S4](#)).

Of the eight CMIs, only WM+TRQ revealed significant differences in FEV₁ compared with WM alone (MD=0.42, 95%CI: 0.22, 0.62, [Table 3](#)). The network

Figure 3 Network plot. (A) Clinical efficacy (B) FEV₁, (C) FEV₁/FVC, (D) FEV₁%, (E) Length of hospital stay.

Abbreviations: WM, conventional Western medical therapy; CKZ, Chuankezhi injection; DH, Danhong injection; DS, Danshen injection; DZXX, Dengzhanxin injection; HH, Honghua injection; HJT, Hongjingtian injection; HQ, Huangqi injection; KA, Kangai injection; KDZ, Kudiezi injection; QKL, Qingkailing injection; RDN, Reduning injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; SHL, Shuanghuanglian injection; SXN, Shuxuening injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanning injection; XBJ, Xuebijing injection; XST, Xuesaitong injection; ZCL, Zhichuanling injection; Salviaolate, Salviaolate injection.

Table 2 The Results of Network Meta-analysis of Clinical Efficacy

OR (95% CI)	WM	WM+CKZ	WM+DH	WM+DS	WM+DZXX	WM+HH	WM+HJT	WM+HQ	WM+KA	WM+KDZ	WM+QKL
WM	I										
WM+CKZ	5.37 (1.93, 12.25) ^a	I									
WM+DH	6.34 (3.02, 11.96) ^a	1.47 (0.39, 3.91)	I								
WM+DS	6.89 (1.33, 22.74) ^a	1.6 (0.21, 6.11)	1.23 (0.19, 4.44)	I							
WM+DZXX	115.4 (1.42, 514) ^a	27.03 (0.25, 116.9)	20.44 (0.21, 92.44)	27.07 (0.18, 126.2)	I						
WM+HH	5.25 (0.75, 19.02)	1.22 (0.12, 5.01)	0.94 (0.11, 3.66)	1.29 (0.08, 6.02)	0.72 (0.01, 4.43)	I					
WM+HJT	15.36 (0.95, 77.41)	3.59 (0.16, 18.94)	2.75 (0.14, 14.33)	3.79 (0.11, 21.22)	2.15 (0.01, 13.97)	5.82 (0.14, 33.05)	I				
WM+HQ	2.21 (0.86, 4.74)	0.51 (0.12, 1.46)	0.39 (0.11, 1.02)	0.54 (0.07, 1.95)	0.3 (0.1, 0.65)	0.83 (0.09, 3.35)	0.53 (0.02, 2.55)	I			
WM+KA	14.96 (0.99, 73.39)	3.5 (0.17, 17.86)	2.67 (0.15, 13.46)	3.6 (0.12, 20.09)	2.02 (0.01, 12.95)	5.61 (0.15, 32.05)	3.52 (0.05, 21.2)	8.16 (0.41, 41.85)	I		
WM+KDZ	6.88 (1.18, 24.15) ^a	1.6 (0.19, 6.45)	1.23 (0.17, 4.67)	1.69 (0.12, 7.76)	0.95 (0.01, 5.77)	2.59 (0.15, 12.57)	1.65 (0.04, 9.18)	3.76 (0.46, 14.88)	1.63 (0.05, 8.9)	I	
WM+QKL	5.86 (1.04, 20.03) ^a	1.36 (0.16, 5.33)	1.05 (0.15, 3.9)	1.44 (0.11, 6.5)	0.81 (0.01, 4.85)	2.21 (0.13, 10.72)	1.4 (0.04, 7.71)	3.2 (0.41, 12.34)	1.39 (0.04, 7.5)	1.55 (0.1, 7.1)	I
WM+RDN	4.65 (2.11, 9.08) ^a	1.08 (0.28, 2.92)	0.83 (0.27, 1.99)	1.14 (0.16, 3.95)	0.64 (0.01, 3.42)	1.75 (0.2, 6.88)	1.11 (0.05, 5.26)	2.53 (0.71, 6.57)	1.1 (0.05, 5.04)	1.22 (0.15, 4.42)	1.41 (0.18, 4.98)
WM+SF	4.87 (1.59, 11.89) ^a	1.13 (0.23, 3.49)	0.87 (0.21, 2.46)	1.2 (0.14, 4.52)	0.67 (0.01, 3.78)	1.83 (0.17, 7.66)	1.16 (0.05, 5.71)	2.66 (0.57, 7.99)	1.16 (0.05, 5.61)	1.29 (0.13, 5.07)	1.47 (0.16, 5.7)
WM+SGM	12.96 (0.76, 65.29)	3 (0.13, 16)	2.3 (0.11, 12.04)	3.19 (0.09, 17.75)	1.76 (0.01, 11.57)	4.92 (0.11, 28.38)	3.15 (0.04, 19.09)	7.01 (0.32, 37.55)	3.15 (0.04, 18.65)	3.37 (0.09, 19.29)	3.88 (0.11, 22.07)
WM+SM	4.51 (1.14, 12.99) ^a	1.05 (0.17, 3.64)	0.81 (0.16, 2.58)	1.11 (0.11, 4.54)	0.62 (0.01, 3.58)	1.71 (0.13, 7.64)	1.08 (0.04, 5.59)	2.46 (0.43, 8.31)	1.07 (0.04, 5.42)	1.19 (0.1, 5.01)	1.37 (0.12, 5.73)
WM+SHL	12.92 (0.85, 64.72)	3 (0.14, 15.91)	2.3 (0.13, 11.9)	3.17 (0.1, 17.66)	1.78 (0.01, 11.62)	4.87 (0.13, 28.5)	3.1 (0.04, 18.82)	7.05 (0.35, 36.75)	3.11 (0.04, 18.92)	3.42 (0.1, 19.23)	3.91 (0.12, 22.12)
WM+SXT	8.69 (0.5, 44.36)	2.04 (0.08, 10.84)	1.55 (0.07, 8.18)	2.15 (0.06, 12.23)	1.21 (0.7, 8.4)	3.33 (0.08, 19.25)	2.09 (0.02, 12.94)	4.73 (0.21, 25.34)	2.08 (0.03, 12.69)	2.3 (0.06, 13.14)	2.63 (0.07, 15.04)
WM+TRQ	4.48 (3.28, 6.02) ^a	1.04 (0.34, 2.41)	0.8 (0.35, 1.56)	1.1 (0.19, 3.46)	0.62 (0.01, 3.19)	1.69 (0.23, 6.1)	1.07 (0.06, 4.8)	2.45 (0.89, 5.39)	1.06 (0.06, 4.59)	1.18 (0.18, 3.9)	1.35 (0.21, 4.4)
WM+XYP	2.93 (0.64, 8.76)	0.68 (0.1, 2.42)	0.52 (0.09, 1.73)	0.72 (0.06, 3)	0.4 (0.2, 3.8)	1.1 (0.08, 5.04)	0.7 (0.02, 3.7)	1.6 (0.25, 5.49)	0.69 (0.02, 3.53)	0.77 (0.06, 3.34)	0.88 (0.07, 3.77)
WM+XBJ	3.52 (1.91, 6.1) ^a	0.82 (0.24, 2.08)	0.63 (0.23, 1.4)	0.86 (0.13, 2.88)	0.48 (0.01, 2.56)	1.33 (0.16, 5.04)	0.84 (0.04, 3.9)	1.92 (0.6, 4.69)	0.83 (0.04, 3.74)	0.93 (0.13, 3.22)	1.06 (0.15, 3.64)
WM+XST	82.43 (0.52, 28.6)	17.99 (0.09, 53.05)	15.58 (0.08, 40.28)	17.17 (0.06, 55.81)	6.33 (0.01, 30.04)	59.16 (0.08, 85.58)	21.27 (0.03, 52.97)	41.88 (0.22, 125.1)	17.74 (0.03, 52.69)	22.32 (0.06, 59.95)	22.45 (0.08, 69.31)
WM+ZCL	7.36 (0.38, 37.47)	1.71 (0.06, 9.09)	1.31 (0.06, 6.91)	1.8 (0.05, 10.11)	1.01 (0.6, 5.1)	2.77 (0.06, 15.95)	1.74 (0.02, 10.62)	4 (0.16, 21.4)	1.76 (0.02, 10.63)	1.95 (0.05, 11.19)	2.24 (0.05, 12.62)

WM +RDN	WM+SF	WM+SGM	WM+SM	WM+SHL	WM+SXT	WM +TRQ	WM+XYP	WM+XBJ	WM+XST	WM +ZCL	WM +Salvianolate
I											
1.2 (0.29,3.42)	I										
3.2 (0.15,16.77)	3.47 (0.14,18.65)	I									
1.12 (0.21,3.6)	1.21 (0.18,4.28)	1.33 (0.04,6.94)	I								
3.22 (0.17,16.58)	3.44 (0.16,18.34)	3.82 (0.05,23.59)	4.19 (0.16,22.9)	I							
2.14 (0.1,11.31)	2.32 (0.09,12.57)	2.54 (0.03,15.88)	2.83 (0.09,15.53)	2.36 (0.03,14.39)	I						
1.11 (0.46,2.24)	1.2 (0.36,2.91)	1.32 (0.07,5.99)	1.46 (0.33,4.03)	1.21 (0.07,5.31)	1.98 (0.1,9.17)	I					
0.72 (0.12,2.43)	0.78 (0.11,2.84)	0.86 (0.03,4.53)	0.95 (0.11,3.69)	0.79 (0.03,4.08)	1.28 (0.04,6.84)	0.67 (0.14,2.04)	I				
0.87 (0.31,1.99)	0.94 (0.25,2.51)	1.03 (0.05,4.84)	1.14 (0.23,3.39)	0.95 (0.05,4.34)	1.55 (0.07,7.4)	0.8 (0.4,1.46)	1.87 (0.34,5.99)	I			
19.3 (0.1,56.43)	22.14 (0.1,61.29)	21.12 (0.03,65.18)	25.91 (0.1,74.21)	15.18 (0.03,59.7)	44.7 (0.05,97.04)	18.3 (0.11,52.22)	40.23 (0.16,122.1)	22.91 (0.14,71.32)	I		
1.82 (0.08,9.53)	1.98 (0.07,10.56)	2.15 (0.02,13.25)	2.42 (0.07,13.38)	1.96 (0.02,11.99)	3.2 (0.03,19.75)	1.68 (0.08,8.62)	3.93 (0.11,21.65)	2.29 (0.1,11.82)	2.59 (0.01,17.35)	I	

(Continued)

Table 2 (Continued).

OR (95% CI)	WM	WM+CKZ	WM+DH	WM+DS	WM+DZXX	WM+HH	WM+HJT	WM+HQ	WM+KA	WM+KDZ	WM+QKL
WM+Salvianolate	2.69 (0.36,10.05)	0.63 (0.06,2.64)	0.48 (0.05,1.93)	0.66 (0.04,3.14)	0.37 (0.2,2.28)	1.02 (0.05,5.14)	0.65 (0.01,3.63)	1.47 (0.14,6.06)	0.63 (0.02,3.51)	0.71 (0.04,3.45)	0.82 (0.04,3.95)

Note: ^aThe 95% CIs of the ORs did not contain 1.

Abbreviations: OR, odds ratio; CI, confidence interval; WM, conventional Western medical therapy; CKZ, Chuankezhi injection; DH, Danhong injection; DS, Danshen injection; DZXX, Dengzhanxin injection; HH, Honghua injection; HJT, Hongjingian injection; HQ, Huangqi injection; KA, Kangai injection; KDZ, Kudiezi injection; QKL, Qingkailing injection; RDN, Reduning injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; SHL, Shuanghuanglian injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanning injection; XBJ, Xuebijing injection; XST, Xuesaitong injection; ZCL, Zhichuanling injection; Salvianolate, Salvianolate injection.

Table 3 The Results of Network Meta-analysis of FEV₁

MD (95%CI)	WM	WM+DZXX	WM+RDN	WM+SM	WM+SXN	WM+SXT	WM+TRQ	WM+XYP	WM+XBJ
WM	0								
WM+DZXX	0.33 (-0.34, 1)	0							
WM+RDN	0.31 (-0.12, 0.75)	-0.02 (-0.82, 0.78)	0						
WM+SM	0.59 (0, 1.18)	0.26 (-0.63, 1.15)	0.28 (-0.46, 1.01)	0					
WM+SXN	0.38 (-0.21, 0.97)	0.05 (-0.84, 0.94)	0.07 (-0.67, 0.8)	-0.21 (-1.05, 0.63)	0				
WM+SXT	0.21 (-0.39, 0.81)	-0.12 (-1.02, 0.78)	-0.1 (-0.84, 0.64)	-0.38 (-1.22, 0.46)	-0.17 (-1.01, 0.67)	0			
WM+TRQ	0.42 (0.22, 0.62) ^a	0.09 (-0.61, 0.79)	0.11 (-0.37, 0.58)	-0.17 (-0.8, 0.45)	0.04 (-0.59, 0.66)	0.21 (-0.42, 0.84)	0		
WM+XYP	0.25 (-0.17, 0.67)	-0.08 (-0.87, 0.71)	-0.06 (-0.67, 0.54)	-0.34 (-1.07, 0.39)	-0.13 (-0.86, 0.6)	0.04 (-0.69, 0.77)	-0.17 (-0.64, 0.3)	0	
WM+XBJ	0.3 (-0.25, 0.85)	-0.03 (-0.9, 0.83)	-0.01 (-0.71, 0.69)	-0.29 (-1.1, 0.52)	-0.08 (-0.89, 0.73)	0.09 (-0.72, 0.9)	-0.12 (-0.67, 0.44)	0.05 (-0.65, 0.75)	0

Note: ^aThe 95% CIs of the MDs did not contain 0.

Abbreviations: MD, mean difference; CI, confidence interval; WM, conventional Western medical therapy; DZXX, Dengzhanxin injection; RDN, Reduning injection; SM, Shenmai injection; SXN, Shuxuening injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanning injection; XBJ, Xuebijing injection.

analysis showed no significant differences between other comparisons.

In the probability rankings, WM+SM (SUCRA=80.18%) was the most likely to improve FEV₁ in the patients with AECOPD, followed by WM+TRQ (SUCRA=66.73%), WM+SXN (SUCRA=58.81%). SUCRA rankings for FEV₁ are presented in [Supplementary Table S3](#).

FEV₁/FVC

In 27 two-arm RCTs, the changes in FEV₁/FVC before and after treatment with 11 CMIs plus WM in 2362

patients with AECOPD were examined. This led to 11 direct and 55 indirect comparisons forming. The network plot for FEV₁/FVC is shown in [Figure 3C](#).

Of the 11 CMIs, WM+DZXX (MD=19.25, 95%CI: 9.15, 29.32), WM+KA (MD=8.14, 95%CI: 0.24, 16.05), WM+RDN (MD=8.8, 95%CI: 4.41, 13.28), and WM+TRQ (MD=6.54, 95%CI: 3.84, 9.27) were more effective than WM alone in improving the FEV₁/FVC in patients with AECOPD. Moreover, WM+DH was inferior to WM+DZXX (MD=17.96, 95%CI: 6.52, 29.43) and WM+RDN (MD=7.52, 95%CI: 0.52, 14.57), whereas WM+DZXX was superior to

WM +RDN	WM+SF	WM+SGM	WM+SM	WM+SHL	WM+SXT	WM +TRQ	WM+XYP	WM+XBJ	WM+XST	WM +ZCL	WM +Salvianolate
0.66 (0.07,2.69)	0.72 (0.06,3.1)	0.8 (0.02,4.54)	0.88 (0.06,3.94)	0.73 (0.02,4.07)	1.19 (0.03,6.74)	0.61 (0.08,2.32)	1.44 (0.09,6.7)	0.83 (0.09,3.26)	0.99 (0.01,6.26)	1.53 (0.03,8.85)	1

WM+QKL (MD = -16.17, 95%CI: -29.36, -2.95), WM+SF (MD = -15.35, 95%CI: -27, -3.7), WM+SXT (MD = -16.51, 95%CI: -29.45, -3.55), WM+TRQ (MD = -12.71, 95%CI: -23.11, -2.25), WM+XYP (MD = -16.39, 95%CI: -28.05, -4.71), and WM+XBJ (MD = -14.8, 95%CI: -26.04, -3.52). The detailed results are shown in [Table 4](#). Other comparisons did not reach statistical significance.

WM+DZXX was ranked the best in FEV₁/FVC (SUCRA=98.55%), followed by WM+RDN (SUCRA=77.15%) and WM+KA (SUCRA=69.47%). SUCRA rankings for FEV₁/FVC are presented in [Supplementary Table S3](#).

FEV₁ %

FEV₁% was reported in 20 two-arm RCTs, including nine CMIs and 1838 patients—forming 9 direct and 36 indirect comparisons. The network plot for FEV₁% is shown in [Figure 3D](#).

WM+RDN (MD=11.5, 95%CI: 6.57, 16.41), WM+TRQ (MD=6.64, 95%CI: 2.58, 10.64), WM+XYP (MD=9.12, 95%CI: 2.57, 15.56), WM+XBJ (MD=8.39, 95%CI: 2.91, 13.79) were significantly superior to WM alone in increasing FEV₁%. Other comparisons did not show significant results. The detailed results are shown in [Table 5](#).

For FEV₁%, WM+RDN (SUCRA=87.28%) was ranked the best, followed by WM+XYP (SUCRA=69.75%), WM+XBJ (SUCRA=64.86%). SUCRA rankings for FEV₁% are presented in [Supplementary Table S3](#).

Length of Hospital Stay

Eight two-arm RCTs including five CMIs and 717 patients recorded the length of hospital stay and formed 5 direct and 10 indirect comparisons. The network plot for length of hospital stay is shown in [Figure 3E](#).

WM+SGM (MD = -6.9, 95%CI: -10.89, -2.9) and WM+TRQ (MD = -3.07, 95%CI: -4.97, -1.15) led to a shorter length of hospital stay than did WM alone

([Table 6](#)). There was no significant difference in other comparisons.

In terms of shortening the length of hospital stay, WM+SGM (SUCRA=94.70%) was ranked the best, followed by WM+SM (SUCRA=57.49%) and WM+XYP (SUCRA=55.85%). SUCRA rankings for length of hospital stay are presented in [Supplementary Table S3](#).

Cluster Analysis Plot for Outcomes

Cluster analysis was performed on clinical efficacy and FEV₁, clinical efficacy and FEV₁/FVC, clinical efficacy and FEV₁%, clinical efficacy and length of hospital stay so as to find the best interventions. The results showed that the most favorable response by WM+DZXX were for clinical efficacy and FEV₁ as well as for clinical efficacy and FEV₁/FVC, by WM+RDN were for clinical efficacy and FEV₁%, and by WM+SGM were for clinical efficacy and length of hospital stay ([Figure 4](#)).

Publication Bias

Begg's test was used to identify the possible publication bias related to the different interventions and the impact of small sample studies. The results demonstrated potential publication bias in the funnel plot of clinical efficacy ($P=0.000$), suggesting that the publication bias was small in the funnel plot for FEV₁ ($P=0.347$), FEV₁/FVC ($P=0.359$), and FEV₁% ($P=0.381$, [Supplementary Figure S5](#)). Because the number of included studies that reported the length of hospital stay was <10, we did not assess the publication bias for length of hospital stay.

Safety

Of the 103 included RCTs, 49 reported regarding adverse reactions, of these 49 studies, 29 reported that no adverse reactions appeared. The remaining 20 studies included 1539 patients and 12 TCM injections. Of the 742 patients who received WM, 50 (6.74%) had the following adverse

Table 4 The Results of Network Meta-analysis of FEV₁/FVC

MD (95% CI)	WM	WM+DH	WM+DZXX	WM+KA	WM+QKL	WM+RDN	WM+SF	WM+SXT	WM+TRQ	WM+XYP	WM+XBJ	WM+XST
WM	0											
WM+DH	1.28 (-4.17, 6.75)	0										
WM+DZXX	19.25 (9.15, 29.32) ^a	17.96 (6.52, 29.43) ^a	0									
WM+KA	8.14 (0.24, 16.05) ^a	6.86 (-2.74, 16.47)	-11.11 (-23.9, 1.71)	0								
WM+QKL	3.07 (-5.44, 11.6)	1.79 (-8.33, 11.9)	-16.17 (-29.36, -2.95) ^a	-5.07 (-16.68, 6.55)	0							
WM+RDN	8.8 (4.41, 13.28) ^a	7.52 (0.52, 14.57) ^a	-10.44 (-21.4, 0.59)	0.66 (-8.36, 9.77)	5.73 (-3.82, 15.38)	0						
WM+SF	3.89 (-1.93, 9.72)	2.61 (-5.36, 10.59)	-15.35 (-27, -3.7) ^a	-4.25 (-14.05, 5.59)	0.82 (-9.49, 11.16)	-4.91 (-12.29, 2.36)	0					
WM+SXT	2.74 (-5.37, 10.83)	1.46 (-8.31, 11.21)	-16.51 (-29.45, -3.55) ^a	-5.4 (-16.74, 5.91)	-0.34 (-12.1, 11.4)	-6.07 (-15.36, 3.12)	-1.16 (-11.14, 8.82)	0				
WM+TRQ	6.54 (3.84, 9.27) ^a	5.26 (-0.82, 11.37)	-12.71 (-23.11, -2.25) ^a	-1.6 (-9.94, 6.78)	3.47 (-5.44, 12.41)	-2.26 (-7.49, 2.92)	2.65 (-3.76, 9.1)	3.8 (-4.71, 12.38)	0			
WM+XYP	2.86 (-3.04, 8.76)	1.58 (-6.44, 9.61)	-16.39 (-28.05, -4.71) ^a	-5.28 (-15.14, 4.57)	-0.21 (-10.59, 10.13)	-5.94 (-13.37, 1.39)	-1.03 (-9.35, 7.28)	0.12 (-9.89, 10.14)	-3.68 (-10.19, 2.78)	0		
WM+XBJ	4.44 (-0.56, 9.5)	3.16 (-4.22, 10.61)	-14.8 (-26.04, -3.52) ^a	-3.7 (-13.03, 5.71)	1.37 (-8.49, 11.28)	-4.36 (-11.08, 2.32)	0.55 (-7.11, 8.27)	1.71 (-7.79, 11.26)	-2.1 (-7.8, 3.62)	1.59 (-6.12, 9.37)	0	
WM+XST	8.1 (0, 16.2)	6.82 (-2.97, 16.59)	-11.15 (-24.05, 1.74)	-0.04 (-11.36, 11.25)	5.03 (-6.76, 16.76)	-0.7 (-9.99, 8.48)	4.21 (-5.79, 14.18)	5.36 (-6.1, 16.83)	1.56 (-7, 10.09)	5.24 (-4.8, 15.22)	3.66 (-5.93, 13.17)	0

Note: ^aThe 95%CI of the MDs did not contain 0.

Abbreviations: MD, mean difference; CI, confidence interval; WM, conventional Western medical therapy; DH, Danhong injection; DZXX, Dengzhanxin injection; KA, Kangai injection; QKL, Qingkailing injection; RDN, Reduning injection; SF, Shenfu injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanning injection; XBJ, Xuebijing injection; XST, Xuesaitong injection.

Table 5 The Results of Network Meta-analysis of FEV₁%

MD (95% CI)	WM	WM+DH	WM+KA	WM+RDN	WM+SF	WM+SXT	WM+TRQ	WM+XYP	WM+XBJ	WM+XST
WM	0									
WM+DH	3.8 (-2.16, 9.78)	0								
WM+KA	5.58 (-2.87, 14.02)	1.78 (-8.57, 12.11)	0							
WM+RDN	11.5 (6.57, 16.41) ^a	7.7 (-0.06, 15.43)	5.92 (-3.85, 15.68)	0						
WM+SF	5.74 (-0.57, 12.07)	1.94 (-6.75, 10.63)	0.17 (-10.38, 10.72)	-5.76 (-13.75, 2.26)	0					
WM+SXT	6.8 (-2.08, 15.66)	3 (-7.71, 13.68)	1.22 (-1.1, 13.45)	-4.7 (-14.84, 5.43)	1.06 (-9.85, 11.94)	0				
WM+TRQ	6.64 (2.58, 10.64) ^a	2.84 (-4.4, 10.01)	1.07 (-8.32, 10.37)	-4.86 (-11.23, 1.47)	0.9 (-6.63, 8.36)	-0.15 (-9.92, 9.56)	0			
WM+XYP	9.12 (2.57, 15.56) ^a	5.32 (-3.57, 14.08)	3.55 (-7.18, 14.13)	-2.38 (-10.57, 5.72)	3.38 (-5.74, 12.39)	2.33 (-8.72, 13.25)	2.48 (-5.19, 10.09)	0		
WM+XBJ	8.39 (2.91, 13.79) ^a	4.59 (-3.55, 12.61)	2.82 (-7.29, 12.82)	-3.11 (-10.47, 4.18)	2.65 (-5.73, 10.94)	1.59 (-8.86, 11.95)	1.75 (-5.02, 8.51)	-0.73 (-9.19, 7.75)	0	
WM+XST	7.59 (-1.01, 16.19)	3.78 (-6.69, 14.24)	2.01 (-10.03, 14.06)	-3.92 (-13.82, 6.02)	1.84 (-8.83, 12.52)	0.79 (-11.56, 13.16)	0.94 (-8.51, 10.48)	-1.54 (-12.25, 9.32)	-0.81 (-10.92, 9.42)	0

Note: ^aThe 95% CIs of the MDs did not contain 0.

Abbreviations: MD, mean difference; CI, confidence interval; WM, conventional Western medical therapy; DH, Danhong injection; KA, Kangai injection; RDN, Reduning injection; SF, Shenfu injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xiyanying injection; XBJ, Xuebijing injection; XST, Xuesaitong injection.

Table 6 The Results of Network Meta-analysis of Length of Hospital Stay

MD (95%CI)	WM	WM+HQ	WM+SGM	WM+SM	WM+TRQ	WM+XYP
WM	0					
WM+HQ	-2.08 (-5.83, 1.67)	0				
WM+SGM	-6.9 (-10.89, -2.9) ^a	-4.82 (-10.28, 0.68)	0			
WM+SM	-3.44 (-7.42, 0.55)	-1.36 (-6.82, 4.11)	3.46 (-2.21, 9.09)	0		
WM+TRQ	-3.07 (-4.97, -1.15) ^a	-0.99 (-5.18, 3.24)	3.83 (-0.61, 8.27)	0.37 (-4.03, 4.79)	0	
WM+XYP	-3.4 (-8.03, 1.22)	-1.32 (-7.25, 4.61)	3.5 (-2.61, 9.59)	0.04 (-6.05, 6.13)	-0.33 (-5.35, 4.67)	0

Note: ^aThe 95%CI of the MDs did not contain 0.

Abbreviations: MD, mean difference; CI, confidence interval; WM, conventional Western medical therapy; HQ, Huangqi injection; SGM, Shengmai injection; SM, Shenmai injection; TRQ, Tanreqing injection; XYP, Xiyanning injection.

reactions: nausea and vomiting (n=16), fever (n=12), gastrointestinal reactions (n=6), rash (n=6), sweating (n=5), xerostomia (n=4), and chest distress (n=1). In contrast, of the 797 patients who received TCM injections plus WM, 55 patients (6.90%) had the following adverse reactions:

nausea and vomiting (n=11), fever (n=8), dizziness (n=4), xerostomia (n=4), gastrointestinal reaction (n=6), phlebitis (n=4), chest distress (n=1), epigastric discomfort (n=2), bellyache (n=2), itchy skin (n=2), rash (n=2), allergy (n=2), local pain during intravenous infusion (n=2),

Figure 4 Cluster analysis plot for outcomes ((A) Clinical efficacy and FEV₁ (B) Clinical efficacy and FEV₁/FVC (C) Clinical efficacy and FEV₁% (D) Clinical efficacy and length of hospital stay)).

Abbreviations: WM; conventional Western medical therapy; CKZ; Chuankezhi injection; DH; Danhong injection; DS; Danshen injection; DZXX; Dengzhanxin injection; HH; Honghua injection; HJT; Hongjingian injection; HQ; Huangqi injection; KA; Kangai injection; KDZ; Kudiezi injection; QKL; Qingkailing injection; RDN; Reduning injection; SF; Shenfu injection; SGM; Shengmai injection; SM; Shenmai injection; SHL; Shuanghuanglian injection; SXN; Shuxuening injection; SXT; Shuxuetong injection; TRQ; Tanreqing injection; XYP; Xiyanning injection; XBJ; Xuebijing injection; XST; Xuesaitong injection; ZCL; Zhichuanling injection; Salvianolate; Salvianolate injection.

Figure 5 Number and incidence of adverse reactions of the included interventions.

Abbreviations: WM; conventional Western medical therapy; CKZ; Chuankezhi injection; HQ; Huangqi injection; QKL; Qingkailing injection; RDN; Reduning injection; SF; Shenfu injection; SM; Shenmai injection; SHL; Shuanghuanglian injection; SXT; Shuxuetong injection; TRQ; Tanreqing injection; XYP; Xianping injection; XBJ; Xuebijing injection; XST; Xuesaitong injection.

palpitation (n=1), headache (n=1), diarrhea (n=1), and dizziness+chest distress+xerostomia (n=2). Of the 12 TCM injections, the highest incidence of adverse reactions was noted after WM+SXT (16.67%), followed by WM+CKZ (11.36%) and WM+RDN (10.45%). Adverse reactions were shown in Figure 5 and Supplementary Table S4. WM alone and TCM injections plus WM both had the following common adverse reactions: fever, nausea and vomiting, xerostomia, gastrointestinal reaction, and rash (Figure 6).

Discussion

This study included 103 RCTs, with 8767 patients and 23 CMIs including CKZ, DH, DS, DZXX, HH, HJT, HQ, KA, KDZ, QKL, RDN, SF, SGM, SM, SHL, SXN, SXT, TRQ, XYP, XBJ, XST, ZCL, and Salvianolate.

In patients with AECOPD, WM+DZXX had the highest likelihood of being the best treatment for improving both the clinical efficacy and FEV₁/FVC, WM+SM, WM+RDN and WM+SGM had the highest likelihood of being the best treatment for improving FEV₁, FEV₁%, and length of hospital stay, respectively.

The cluster analysis revealed that WM+DZXX had the most favorable response for clinical efficacy and FEV₁, as well as clinical efficacy and FEV₁/FVC, WM+RDN had the most favorable response for clinical efficacy and

FEV₁%, WM+SGM had the most favorable response for clinical efficacy and length of hospital stay.

DZXX is a sterile aqueous solution composed of *Erigerontis Herba* extract, has been used in China for many years. Its main active components include flavonoids and phenolic acids.³¹ Flavonoids can activate blood and dissolve stasis as well as inhibit the inflammatory reaction in the lung and the synthesis of collagen fiber to prevent pulmonary fibrosis.³² Clinical studies have shown that compared with WM alone, DZXX achieved better efficacy when administered to patients with moderately severe COPD, it could not only reduce inflammation, but also improve hemorheological indicators and lung function.³³ Experimental studies show that DZXX can decrease transforming growth factor β 1 activity to inhibit fibroblast proliferation, collagen fiber and extracellular matrix synthesis, delaying or improving the process of airway remodeling and irreversible obstruction in COPD.^{34–36}

RDN is composed of *Artemisiae Annuae Herba*, *Lonicerae Japonicae Flos*, and *Gardeniae Fructus*, is generally administered as an intravenous injection to treat cold, cough, upper respiratory infections, and acute bronchitis, and it has a good curative effect in clinics.^{37,38} Previous studies have shown that cryptochlorogenic acid, neochlorogenic acid, and geniposide—the main active substances of RDN^{39–44}—can increase superoxide dismutase (SOD) activity, suppress myeloperoxidase (MPO)

Figure 6 Adverse reactions after WM alone and TCM injections plus WM.
Abbreviation: WM; conventional Western medical therapy.

activity, and reduce the wet/dry (W/D) ratio and total leukocyte and neutrophil numbers,³⁸ it can thus be anti-inflammatory, improve immunity, and alleviate damage caused by the diseases.^{45,46} In addition, a network analysis identified two key compounds (CFA and ferulic acid), five key targets (Bcl-2, eNOS, PTGS2, PPARA, and MMPs), and four key pathways (estrogen signaling pathway, PI3K-AKT signaling pathway, cGMP-PKG signaling pathway, and calcium signaling pathway) for RDN—all of which play critical roles in the treatment of inflammatory diseases.⁴⁷

The normal respiratory movement of the human body involves the joint participation of nerve cells that produces the respiratory rhythm and those that regulate the respiratory movement in the central nervous system.⁴⁸ Studies have shown that the irreversible airflow limitation of COPD may be related to the abnormal excitability of the respiratory center.⁴⁸ SGM is composed of Red Ginseng, *Ophiopogonis Radix*, and *Schisandrae Chinensis*

Fructus. Here, *Ophiopogonis Radix* nourishes the yin (nutrition and fluid in the human body, which nourishes various organs⁴⁹), *Schisandrae Chinensis Fructus* astringents the qi (vital energy, regarded as a driving force of biological activities in the human body, including both nutrient substances and organ functions⁵⁰) and has antitussive effects, and Red Ginseng tonifies qi and enhances immunity.⁵¹ The combination of these herbs affects the respiratory center and then relieves dyspnea in COPD patients.^{52,53} Modern studies have also indicated that SGM can improve pulmonary ventilation function, thus increasing the alveolar diffuse area, adjusting the airflow ratio, reducing myocardial oxygen consumption and glucose metabolism, and enhancing gland and endocrine function, as a result, the whole body function is adjusted, qi becomes tonified and blood is activated.⁵⁴ A meta-analysis reported that SGM+WM has significant efficacy in COPD treatment, where it improves clinical efficacy and lung function, regulates immune function, and shortens disappearance time of lung rales.^{55,56}

Adverse reactions appeared in both treatment group and control group of included studies. However, the specific correlation between the TCM injections used and adverse reactions could not be determined. The incidence of adverse reactions was high in WM+SXT (16.67%), WM+CKZ (11.36%), and WM+RDN (10.45%), compared with WM alone. Thus, the safety of CMIIs still needs further evaluation.

Limitations

The number of original studies on this research topic met the basic requirements for this NMA, but the quality of these studies were not high. In particular, the limitations of our study were as follows:

- (1) Only 31.07% of the studies used the correct random method, which may have resulted in selective biases.
- (2) Most of the studies did not mention the blinding of participants or personnel and allocation concealment, which may have resulted in implementation biases.
- (3) Of all the included studies, 15.53% merely used subjective indicators as the outcome evaluation index, which may have resulted in measurement bias.
- (4) The 103 included studies did not mention protocol registration and conflict of interests, therefore, the sources of other bias could not be determined.
- (5) The funnel plot for clinical efficacy indicated the possibility of publication bias. The missing contents from ongoing studies and gray literature may result in publication bias.⁵⁵
- (6) None of the included studies restricted the TCM syndromes of AECOPD patients. However, patients with different TCM syndromes who were treated with the same intervention may not represent the real effect of the TCM drugs.
- (7) The participant age and treatment duration varied in the included studies, which may have affected the stability of results.
- (8) All included studies were conducted in China, this might weaken the generalization of the results.

Conclusion

In conclusion, WM+DZXX had the highest likelihood of being the best treatment for improving both the clinical efficacy and FEV₁/FVC, WM+SM, WM+RDN and WM+SGM had the highest likelihood of being the best treatment for improving FEV₁, FEV₁% and length of hospital stay, respectively. Combined with cluster analysis results, DZXX, RDN or SGM plus WM were noted to be the optimum treatment regimens for improving the condition

of patients with AECOPD. However, the quality of studies evaluating the efficacy of various CMIIs is not good. Therefore, additional high-quality studies are warranted.

Abbreviations

COPD, chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; TCM, traditional Chinese medicine; CMI, Chinese medical injection; RCT, randomized controlled trial; CKZ, Chuankezhi injection; DH, Danhong injection; DS, Danshen injection; DZXX, Dengzhanxixin injection; HH, Honghua injection; HJT, Hongjingtian injection; HQ, Huangqi injection; KA, Kangai injection; KDZ, Kudiezi injection; QKL, Qingkailing injection; RDN, Reduning injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; SHL, Shuanghuanglian injection; SXN, Shuxuening injection; SXT, Shuxuetong injection; TRQ, Tanreqing injection; XYP, Xianping injection; XBJ, Xuebijing injection; XST, Xuesaitong injection; ZCL, Zhichuanling injection; Salvianolate, Salvianolate injection; WM, conventional Western medical therapy; ADR, adverse reaction; FEV₁, forced expiratory volume in one second; FEV₁/FVC, ratio of forced expiratory volume in one second to forced vital capacity; FEV₁%, ratio of forced expiratory volume in one second to the predicted value.

Data Sharing Statement

The raw data supporting the conclusion of this article will be made available by the corresponding author (Hui Wang) without undue reservation.

Ethics Approval and Consent to Participate

This study is an overview of the literature thus ethics approval was not needed.

Consent to Publish

The study group consented to publish.

Acknowledgments

Thanks to the authors of the included studies to provide primary data.

Funding

This overview was funded by the Special Support Plan for Talent Development of Tianjin—Young Top Talent Project (No. 201504)/ Training Program of Innovation Team of

Tianjin Higher Education Institution through Tianjin Municipal Education Commission (No. TD13-5047).

Disclosure

The authors report no conflicts of interest in this work.

References

- Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. *Chest*. 2000;117(5):398S–401S. doi:10.1378/chest.117.5_suppl_2.398S
- Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. *Eur Respir J Suppl*. 2003;21(Supplement41):46S–53S. doi:10.1183/09031936.03.00078002
- Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:21–30. doi:10.2147/COPD.S85978
- Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. *Am J Resp Crit Care*. 2008;178(4):332–338. doi:10.1164/rccm.200712-1869OC
- Min L, Yang Z, Dan-Dan L, Jing S. Traditional care interventions to reduce readmission in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. *Chin Nursing Res*. 2017;4(2):84–91. doi:10.1016/j.cnre.2017.06.004
- Milavetz G. Global Surveillance; Prevention and Control of Chronic Respiratory Diseases: a Comprehensive Approach. *J Pharm Tech*. 2008;24(2):122.
- Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. *Lancet*. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
- Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. *Expert Rev Anti Infect Ther*. 2006;4(1):101–124. doi:10.1586/14787210.4.1.101
- Lim S, Lam DC, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. *Asia Pac Fam Med*. 2015;14(1):4. doi:10.1186/s12930-015-0020-9
- Shilian H, Jing W, Cui C, Xinchun W. Epidemiological analysis of chronic diseases in Chinese residents. *Chin J Clin Healthcare*. 2020;23(3):8–13.
- Writing Group of Expert Consensus on Anti-infective Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Expert consensus on anti-infective therapy for acute exacerbation of chronic obstructive pulmonary disease in China. *Int J Respir*. 2019;39(17):1281–1296.
- Chen W, Jianying X, Lan Y, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
- Yao C, Liu X, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. *Int J Chronic Obstr*. 2017;12:2285–2290.
- Global Initiative For Chronic Obstructive Lung Disease. Global strategy for the diagnosis; management; and prevention of chronic obstructive pulmonary disease (2021 report). Available from: <https://goldcopd.org/2021-gold-reports/>. Accessed August 18, 2021.
- Polverino F, Kheradmand F. COVID-19; COPD; and AECOPD: immunological; Epidemiological; and Clinical Aspects. *Front Med*. 2021;7:627278. doi:10.3389/fmed.2020.627278
- Wang L, Fan Y, Xu J, Deng H, Jia B. The efficacy and safety of Tanreqing injection combined with western medicine for severe pneumonia: a protocol for systematic review and meta-analysis. *Medicine*. 2020;99(35):e22010. doi:10.1097/MD.00000000000022010
- Xianghua G. The research progress of COPD with catabasis. *Nei Mongol J Traditional Chin Med*. 2017;18(36):123–124.
- Peng YQ, Mao YM, Zhu JQ, et al. A clinical study of short-term Xuebijing injection on treatment of patients with acute exacerbation of chronic obstructive pulmonary disease. *Chin J Integr Traditional Western Med Intensive Critical Care*. 2008;3:178–180.
- Duan L, Ning C. Observation Curative Effect of Xuebijing Injection Synergistic in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *China Continuing Med Educ*. 2015;7(31):219–220.
- Xie S, Yan P, Yao C, et al. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial. *Trials*. 2019;20(1):136. doi:10.1186/s13063-019-3204-z
- Chen SQ, Yang XY, Tang XY, et al. Systematic review of Chuankezhi injection for treating acute exacerbation of chronic obstructive pulmonary disease. *China J Chin Materia Medica*. 2017;42(14):2789–2795. doi:10.19540/j.cnki.cjcm.20170523.009
- Gao LN, Lyu J, Wang ZF, Yu DD, Sun MH. Meta-analysis of randomized controlled trials on effect of Tanreqing Injection combined with Western medicine on acute exacerbation of chronic bronchitis. *China j Chin materia medica*. 2019;44(24):5313–5321. doi:10.19540/j.cnki.cjcm.20190924.501
- Huang X, Duan X, Wang K, Wu J, Zhang X. Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Complement Ther Med*. 2019;43:140–147. doi:10.1016/j.ctim.2019.01.020
- Gong G, Li X. Study of clinical effect on treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing injection and cell factor level. *China j Chin materia medica*. 2009;34(1):104–106.
- Wang TJ, Xie ZH, Zhao ZZ. Effects of shuxuening injection on the levels of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute exacerbated chronic obstructive pulmonary disease patients. *Chin j Integrated Trad Western Med*. 2012;32(2):191–194.
- Chinese Society of Respiratory Diseases. Diagnosis and treatment guidance of chronic obstructive pulmonary disease. *Chin J Tuberculosis Respir Dis*. 2013;36(4):255–264.
- Hosseini HM, Pai DR, Ofak DR. COPD: does Inpatient Education Impact Hospital Costs and Length of Stay? *Hosp Top*. 2019;97(4):165–175. doi:10.1080/00185868.2019.1677540
- Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. *BMC Med*. 2013;11(1):181. doi:10.1186/1741-7015-11-181
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343(oct182):d5928. doi:10.1136/bmj.d5928
- Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015;162(11):777–784. doi:10.7326/M14-2385

31. Hua F, Peng L, Qiang K, Zhi-Long Z, Ji W, Jia-Yi C. Metabolism and Pharmacological Mechanisms of Active Ingredients in *Erigeron breviscapus*. *Curr Drug Metab*. 2021;22(1):24–39. doi:10.2174/1389200221666201217093255
32. Juan J, Qiangjin G, Nianzhi Z. Experimental Research Progress in Chinese Herbal Medicines with the Effects of Benefiting Qi and Activating Blood Circulation and Their Active Ingredients in Treating Pulmonary Fibrosis. *Chin J Inf TCM*. 2015;22(9):131–134.
33. Junping S. Hemorheology and pulmonary function analysis of *Erigeron breviscapus* injection in the treatment of moderate and severe chronic obstructive pulmonary disease in the elderly during stable period. *J Electrocardiogram*. 2018;7(4):101–103.
34. Fei D, Gang H, Daigang C, Huajun Y. Effects of Breviscapine on airway remodeling in rats with chronic obstructive pulmonary disease model. *Hebei J Trad Chin Med*. 2017;39(7):1069–1073.
35. Chua F, Sly PD, Laurent GJ. Pediatric lung disease: from proteinases to pulmonary fibrosis. *Pediatr Pulm*. 2005;39(5):392–401. doi:10.1002/ppul.20171
36. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. *Am J Physiol Lung Cell Mol Physiol*. 2007;293(3):L525–34. doi:10.1152/ajplung.00163.2007
37. Guoliang Z, Jie Z, Liyun H, Shiyan Y, Ziqiang Z. Reduning injection for fever; rash; and ulcers in children with mild hand; foot; and mouth disease: a randomized controlled clinical study-ScienceDirect. *J Tradit Chin Med*. 2013;33(6):733–742. doi:10.1016/S0254-6272(14)60005-4
38. Luping T, Wei X, Yifang L, et al. Anti-inflammatory effects of Reduning Injection on lipopolysaccharide-induced acute lung injury of rats. *Chin J Integr Med*. 2014;20(8):591–599. doi:10.1007/s11655-014-1758-x
39. Gao W, Wang S, Cui Z, Cao J, Tian H. Reduning injection for community-acquired pneumonia: meta-analysis. *China J Chin Materia Medica*. 2011;36(24):3539.
40. Chang XJ, Zhang S, Chen J, et al. Effect of Reduning Injection on Acute Lung Injury of Rats. *Chin J Exp Trad Med Formulae*. 2014;20(8):591–599.
41. Jian C, Xiujuan C, Chunmiao C, et al. Study on Analgesic and Antipyretic Effect of Re-Du-Ning Injection. *Modernization Traditional Chin Med Materia Medica World Sci Tech*. 2014;16(9):1912–1915.
42. Sha W, Ye J, Qian L, Liu QA, Wei X. On-line quantitative monitoring of liquid-liquid extraction of *Lonicera japonica* and *Artemisia annua* using near-infrared spectroscopy and chemometrics. *Pharmacogn Mag*. 2015;11(43):643–650. doi:10.4103/0973-1296.160465
43. Fang W, Li CY, Zheng YF, Li HY, Xiao W, Peng GP. Identification of the Allergenic Ingredients in Reduning Injection by Ultrafiltration and High-Performance Liquid Chromatography. *J Immunol Res*. 2016;2016(2):1–7.
44. Wu RS, Tao L, Qin PP, Ling Y, Yan Z. Physical fingerprint for quality control of Reduning injection. *China j Chin materia medica*. 2017;42(3):505. doi:10.19540/j.cnki.cjcmm.20170103.020
45. Yejing Z. Effect of Reduning Injection Combined with Cefotaxime Sodium on Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection. *J Qiqihar Med Univ*. 2018;39(24):2899–2901.
46. Yufeng W, Zhongbin Z. Therapeutic effect of Reduning injection on acute upper respiratory tract infection. *Evaluation Analysis Drug Use Hospitals China*. 2017;17(8):1052–1053.
47. Fuda X, Mingxiang X, Yibing Y, et al. Assessing the Anti-inflammatory Mechanism of Reduning Injection by Network Pharmacology. *Biomed Res Int*. 2020;2020(4):1–13.
48. Jolley CJ, Luo YM, Steier J, Reilly C, Moxham J. Neural respiratory drive in healthy subjects and in COPD. *Eur Respir J*. 2009;33(2):289–297. doi:10.1183/09031936.00093408
49. Kang YM, Seo MG, Lee KY, An HJ. Antiphotoreactive Potential of Extracts of Yin-Tonic Herbal Medicine in Skin Cell and Human Skin Equivalent. *Evid Based Compl Alt*. 2020;20(2020):8881270.
50. Wang XM, Xiao-Bo LI, Peng Y. Impact of Qi -invigorating traditional Chinese medicines on intestinal flora: a basis for rational choice of prebiotics. *Chin J Nat Med*. 2017;15(4):241–254. doi:10.1016/S1875-5364(17)30041-9
51. Qing F. Effects of Shenmai injection on serum migration inhibitory factor and tuillor necrosis factor—d levels in patients with acute viral myocarditis and its significance. *Chin j Ethnomed Ethnopharm*. 2010;19(5):31–32.
52. Xiaoli L, Xiaoyun L, Zhongtao L, et al. Effect of Shengmai Injection on Phrenic Nerve Discharge of COPD rats. *J Shaanxi Univ Chin Med*. 2017;40(2):71–74.
53. Haopeng Y, Long L, Chengzhi C, Junping K, Boyang Y, Yongqing Y. Neuroprotective Effect of Shengmai Injection on Expression of Tissue Factor and related Signal Pathways in Mice with Cerebral Ischemia-reperfusion Injury. *Chin J Exp Trad Med Formulae*. 2013;19(14):194–199.
54. Guangrong N. Shengmai Injection Combined with Western Medicine in the Treatment of Lung and Kidney Yin Deficiency of Two Chronic Obstructive Pulmonary Disease Randomized Controlled Study. *J Pract Traditional Chin Internal Med*. 2016;30(12):69–71.
55. Xingyue H, Xiaojiao D, Kaihuan W, Jiarui W, Xiaomeng Z. Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Complement Ther Med*. 2019;43(1):140–147.
56. Chen L, YingJia LU. Influence of Shengmai Injection on the Inflammatory Factors of Patients with Chronic Obstructive Pulmonary Disease. *Henan Traditional Chin Med*. 2016;36(3):538–539.
57. Lili C, Jinhui L, Demei L, Jiangang X. Clinical observation of Kang'ai injection in the treatment of elderly patients with AECOPD. *J Clin Pulmonary Med*. 2014;19(7):1247–1250.
58. Weizhong C, Ji L. Efficacy of Reduning Injection on AECOPD: A Clinical Observation of 77cases. *Guiding J Traditional Chin Med Pharm*. 2014;20(13):69–71.
59. Zhu C, Zhong L. Influence of Danghong injection on TNF-alpha and IL-8 of patients with chronic obstructive pulmonary disease in acute exacerbation. *J Liaoning Med Univ*. 2013;34(1):23–25.
60. Yongsheng C. Clinical observation of Shenfu injection in adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease. *J Em Trad Chin Med*. 2015;24(3):553–554.
61. Yandong C, Junhe W. The ameliorative effect of Chuankezhi injection on acute exacerbation of chronic obstructive pulmonary disease. *Clin J Traditional Chin Med*. 2010;22(5):419–420.
62. Hongzhen D, Wei Z. The Clinical Curative Effect of Reduning Injection treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease (Syndrome of Phlegm Heat Obstructing in the Lung). *J Em Trad Chin Med*. 2015;24(8):1433–1435.
63. Du J. Effect of Danhong injection on acute exacerbation of chronic obstructive pulmonary disease. *China Practical Med*. 2014;9(32):135–136.
64. Yong D, Zhijun J, Wei H. Study of influence of Tanreqing injection on serum high-sensitivity C- reactive protein and procalcitonin of patients with acute exacerbation of chronic obstructive pulmonary disease. *Chin J Nosocomiol*. 2015;25(6):1233–1235.
65. Limin D, Chaozhi N. Observation Curative Effect of Xuebijing Injection Synergistic in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *China Continuing Med Educ*. 2015;7(31):219–220.
66. Yongxia F. Observation of curative effect of Danhong injection on acute attack of COPD. *J North Pharm*. 2011;8(9):17–18.
67. Qing F. Observation on the curative effect of Tanreqing on acute exacerbation of chronic obstructive pulmonary disease. *J Clin Ration Drug Use*. 2015;8(7B):48–49.

68. Zhijun F, Wei T. Effects of Tanreqing Injection on Expression of Serum C-reactive Protein (CRP); IL-8 and IL-17 in Patients with Acute Exacerbation of COPD. *China Foreign Med Treat*. 2010;29(19):83–84.
69. Dongwei F. Clinical observation of Tanreqing injection in the treatment of acute exacerbation of chronic obstructive pulmonary. *J Em Trad Chin Med*. 2012;21(8):1298.
70. Qin F, Li L, Fang T. Tanreqing combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease in elderly patients. *J Em Trad Chin Med*. 2009;18(1):120–121.
71. Yongwang F. Clinical observation of Tanreqing injection in the treatment of acute exacerbation of COPD. *China Med Herald*. 2009;6(33):147.
72. Zongkai G. Analysis of curative effect of Tanreqing injection on acute exacerbation of chronic obstructive pulmonary disease. *China Practical Med*. 2015;10(33):194–195.
73. Zongkai G. Application value of Danhong injection in the treatment of acute episode of COPD. *Med Forum*. 2016;20(9):1190–1191.
74. Xia G, Daiqi P. Clinical effect of integrated traditional Chinese and western medicine on acute exacerbation of chronic obstructive pulmonary disease. *Chin J Modern Drug App*. 2009;3(15):153–154.
75. Fang H, Xin Z. Efficacy of Xiyanning in the treatment of acute exacerbation of chronic obstructive pulmonary disease. *Mod J Integr Trad Chin Western Med*. 2015;24(8):870–872.
76. Tianpao H, Feiyu L, Yinru L. Clinical Observation of Xuebijing treating Acute Exacerbation of Chronic Obstructive Pulmonary Diseases. *Chin Arch Traditional Chin Med*. 2010;28(10):2232–2233.
77. Shaoling H. Efficacy of Xuebijing injection in treating acute exacerbation period of chronic obstructive pulmonary disease patients and the effect on levels of SP-D and CCL18. *Jilin Med J*. 2019;40(5):925–927.
78. Xiang H. Clinical Observation on Tanreqing Injection combined with Conventional Western Medicine in Treatment of Chronic Obstructive Pulmonary Disease in Acute Exacerbation. *J Hubei Univ Chin Med*. 2016;18(5):74–76.
79. Yongliang H, Juhua M. Observation of effect of Danshen injection on acute exacerbation of chronic obstructive pulmonary disease. *J Clin Ration Drug Use*. 2012;5(19):100–101.
80. Xiaolin H, Xiaobin D, Zhenghua K, Jing T, Shiyang Z. Comparison of Tanreqing and Xuebijing in treatment of acute exacerbation of chronic obstructive pulmonary disease. *Drugs Clinic*. 2016;31(11):1732–1736.
81. Wenshan H. Tanreqing injection in treating 20 cases of acute onset of chronic obstructive pulmonary disease. *Hunan J Traditional Chin Med*. 2014;30(2):32–34.
82. Bin H, Qixiang H, Dongsheng L, Shanmao X. Clinical study of Tanreqing injection in the treatment of acute exacerbation of chronic obstructive pulmonary. *J Em Trad Chin Med*. 2006;15(5):464–466.
83. Jin K, Yi Y. The effect analysis of phlegm heat injection auxiliary treatment of elderly AECOPD. *J Front Med*. 2016;6(26):30–31.
84. Daixiang L. Clinical efficacy of Xuebijing in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). *Capital Med*. 2015;22(8):47.
85. Guolin L, Nianzhi Z, Wei R. Clinical observation of Tanreqing in the treatment of AECOPD. *J Clin Pulmonary Med*. 2009;14(3):416.
86. Linlin L, Qianlong X, Baoli X, Yunfeng L, Shuchi H. Clinical observation of Tanreqing in treating patients with acute onset of chronic obstructive pulmonary disease. *J Ningxia Med Coll*. 2014;36(2):204–206.
87. Wen LI, Bing M, Gang W, et al. Effect of Tanreqing injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. *Chin J Integr Med*. 2010;16(2):131–137. doi:10.1007/s11655-010-0131-y
88. Gang L. Clinical observation of Danshen injection in adjuvant treating patients with acute exacerbations of chronic obstructive pulmonary disease. *Nei Mongol J Traditional Chin Med*. 2009;28(14):21–22.
89. Wei L, Sining C, Ruixiang L. Effects of Tanreqing Injection on hs-CRP, IL-6, IL-10 in acute exacerbation of Chronic Obstructive Pulmonary Disease. *J Guangxi Univ Chin Med*. 2017;20(1):11–13.
90. Wensheng L, Weiqing L, Shiwei C, Qingshun H. Influence of Shenfu injection on tumor necrosis factor— α , interleukin—2 and lung function in patients with chronic obstructive pulmonary disease at acute exacerbation stage. *Chin J Integr Traditional Western Med Intensive Critical Care*. 2008;15(3):149–151.
91. Daobo L, Hongli Y, Wenteng C, Min L. Effect of Xuebijing injection on chronic obstructive pulmonary disease and blood coagulation function. *China Trop Med*. 2009;9(8):1514–1515.
92. Hongbo L. Clinical observation of Tanreqing in treating 60 cases of acute onset of chronic obstructive pulmonary disease. *J Em Trad Chin Med*. 2008;17(4):448–449.
93. Honghong L, Shirong D, Jin L, Ainn L. The clinical observations of Xiyanning as an adjuvant therapy on acute exacerbation of chronic obstructive pulmonary disease. *J Trop Med*. 2016;16(10):1293–1295.
94. Yan L, Lili D, Binbin Q, et al. Effect of Shuxuetong Injection on “Inflammatory Factor - Vascular Endothelial Function - Hemorheology” Network in AECOPD Patients. *Mod J Integr Trad Chin Western Med*. 2019;28(2):165–169.
95. Zhanxiang L, Anmeng W. Effect of Tanreqing injection in treatment of 100 patients with the exacerbation of chronic obstructive pulmonary disease. *China Pract J Med*. 2007;34(24):27–28.
96. Zonggui L. Analysis of curative effect of Tanreqing injection on acute exacerbation of chronic obstructive pulmonary disease. *Henan Med Res*. 2014;23(3):121–123.
97. Hai L. Clinical observation on tanreqing injection in treating 124 cases of acute exacerbation of chronic obstructive pulmonary. *J Em Trad Chin Med*. 2012;21(6):966.
98. Na L, Meixia W, Lina D, Shuyuan A. Clinical Observation of Tanreqing Injection in Treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the Elderly Respiratory Ward. *Guide China Med*. 2013;11(24):420–421.
99. Lin M. Observation of curative effect of Xuebijing injection on acute exacerbation of chronic obstructive pulmonary disease. *Chin J Clin Rational Drug Use*. 2014;7(9):142–143.
100. Lijian P, Zang N, Liu C, Zheng W, Lu X. Anti-inflammatory and Immunization Properties of Re-Du-Ning Injection in Treatment of AECOPD with Phlegm-heat Stagnated in the Lung Syndrome. *Modernization Traditional Chin Med Materia Medica World Sci Tech*. 2015;17(6):1225–1229.
101. Bo P, Nianzhi Z, Hongyan J, Guolin L, Wei R, Wei C. Effect of Tanreqing on pulmonary function of acute exacerbation of COPD (Syndrome of retention of phlegm and heat in Fei). *J Em Trad Chin Med*. 2007;16(12):1456–1457.
102. Qin Q, Xinjun F, Yang P, et al. Clinical research of Xuebijing parenteral solution on the coagulation status and lung function of patients with acute exacerbation of chronic obstructive pulmonary disease. *Chin J Critical Care Med*. 2013;33(6):543–545.
103. Qiu Q, Jian X, Shuyun L. Therapeutic Effect of Sofren Injection in Treatment of Acute Exacerbations of COPD. *Chin Med Innovations*. 2014;11(32):14–16.
104. Yuejuan R, Xuemei L, CMmei Z. Clinical observation of Shenfu Injection in the treatment of acute exacerbation chronic obstructive pulmonary disease. *Nei Mongol J Traditional Chin Med*. 2013;32(7):58–59.
105. Ce S. Tanreqing injection in the treatment of 50 cases of acute chronic obstructive pulmonary disease. *China Pract J Med*. 2009;36(9):54–55.

106. Daihui S. Evaluation on the efficacy of Tanreqing on 42 patients with chronic obstructive pulmonary disease of acute exacerbation. *Youjiang Med J*. 2013;41(1):23–24.
107. Yiyang S. Observation of curative effect of Danhong injection on acute exacerbation of chronic obstructive pulmonary disease. *J Em Trad Chin Med*. 2009;18(8):1232–1233.
108. Liang S, Liangwei F. Clinical experience of Chuankezhi injection in the treatment of chronic obstructive pulmonary disease. *Nei Mongol J Traditional Chin Med*. 2012;31(5):26–27. doi:10.1186/1479-5876-10-26
109. Jin S, Tao S. Observation on curative effect of Tanreqing injection on acute attack of chronic obstructive pulmonary disease. *J Em Trad Chin Med*. 2008;17(8):1050.
110. Na T, Qiangmin C. Observation on the Therapeutic Effect of Removing Heat-phlegm Method in the Sequential Treatment of Chronic Obstructive Pulmonary Disease in Acute Exacerbation Period. *Guangming J Chin Med*. 2016;22(31):3231–3233.
111. Wei T. Clinical observation on the treatment of acute exacerbation of chronic obstructive pulmonary disease by integrated traditional Chinese and western medicine. *Modern Med J China*. 2012;14(3):1016–1017.
112. Rukang T, Xianghua T, Xiaohong L, Yunxia R. Therapeutic effect of Shenmai injection on 38 cases of chronic obstructive pulmonary disease during acute episode. *Chin J Modern Drug App*. 2009;3(11):134–135.
113. Tulei T. Clinical Study of Reduning Treatment of Acute Exacerbation Phase of Chronic Obstructive Pulmonary Disease. *J Heze Med Coll*. 2015;27(2):66–68.
114. Aidong W. Clinical observation of Tanreqing injection in treating 72 cases of acute exacerbation of chronic obstructive pulmonary disease. *J Med Theory Pract*. 2011;24(6):664.
115. Haiyan W. Observation of therapeutic effect of Danzhanxixin injection on acute exacerbation of chronic obstructive pulmonary disease. *J New Chin Med*. 2010;42(11):10–11.
116. Lixia W, Qingyun L. Therapeutic effect of Tanreqing injection on 50 cases of acute exacerbation of COPD. *Chin J Modern Drug App*. 2008;2(21):38.
117. Qiu W, Jishan Q. Clinical observation on Tanreqing adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease. *J Modern Med Health*. 2013;29(22):3491.
118. Tiejun W, Zhonghua X, Zhenzhong Z. Effects of Shuxuenling Injection on the Levels of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Acute Exacerbated Chronic Obstructive Pulmonary Disease Patients. *Chin J Integr Traditional Western Med*. 2012;32(2):191–194.
119. Tongbing W. Effects of Tanreqing injection on acute exacerbations of chronic obstructive pulmonary disease. *China Pract J Med*. 2015;42(017):32–33.
120. Xianghua W, Xiaojun L. Clinical observation on 39 cases of acute exacerbation of chronic obstructive pulmonary disease treated with integrated traditional Chinese and western medicine. *Guiding J Traditional Chin Med Pharmacol*. 2011;17(7):29–32.
121. Xueqin W. Application of Xuebijing injection in acute exacerbation of chronic obstructive pulmonary disease. *Pract Clin J Integr Trad Chin Western Med*. 2015;15(5):18–19.
122. Yong W, Chunming S, Yong L. Clinical observation of Shengmai injection in acute exacerbations of chronic obstructive pulmonary disease(COPD). *Chin J New Drugs*. 2007;16(16):1298–1300.
123. Sizun W, Sining C, Yuan F. Effect of Tanreqing Injection on Cytokines and Lung Function in Patients with acute exacerbation of Chronic Obstructive Pulmonary Disease. *J Em Trad Chin Med*. 2011;20(9):1402–1403.
124. Yaomin W. Clinical analysis of Reduning injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease. *Shenzhen J Integr Traditional Chin Western Med*. 2014;24(5):29–30.
125. Yunjun W. Effect of Xuebijing in the treatment of acute exacerbation of chronic obstructive pulmonary disease and its mechanism. *Jilin Med J*. 2012;33(10):2107–2108.
126. Beishou W, Minqiang H. Clinical study on salvinolate injection in treatment of acute exacerbation of chronic obstructive pulmonary disease. *Drugs Clinic*. 2015;30(12):1498–1501.
127. Dengxiang W. Clinical observation of 100 cases of acute exacerbation of chronic obstructive pulmonary disease treated with integrated traditional Chinese and western medicine. *Contemporary Med*. 2015;21(31):157–158.
128. Yi W, Fenghua Q, Lei Z, Yao X, Yimin Q. Effects of Chuankezhi injection with airway humidification on mechanical ventilation function of patients with acute exacerbation of chronic obstructive pulmonary disease. *Shanghai J Trad Chin Med*. 2017;51(4):57–58.
129. Chunxia X, Xiaohong S. 40 cases of acute exacerbation of COPD treated by Kudiezi injection combined with western medicine. *Fujian J Traditional Chin Med*. 2010;41(2):17–18.
130. Wei X. Clinical observations on treating respiratory system emergency by Chuankezhi Injection. *Chin J Exp Trad Med Formulae*. 2012;18(6):252–254.
131. Zhi X, Wei H, Jianbin H, Maofeng X. Observation on curative effect of Tanreqing injection on patients with acute exacerbation of chronic obstructive pulmonary. *J Em Trad Chin Med*. 2020;29(2):300–302.
132. Chenxi X, Xiaoxing L. Effects of Acupoint Injection of Astragali Radix Injection on Immune and Respiratory Function of Patients with Sequential Mechanical Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Chin J Information Traditional Chin Med*. 2018;25(8):17–21.
133. Yonghong X, Faguang J, Tonggang L, Enqing F, Yani S. Clinical observation of Tanreqing injection in the treatment of acute exacerbation of chronic obstructive pulmonary. *J Em Trad Chin Med*. 2005;14(4):291–292.
134. Sugiong X, Yaping G, Xi X. Influence of astragalus injection on serum cytokines and lung function in acute exacerbation of chronic obstructive pulmonary disease. *Modern Chin Doctor*. 2013;51(9):43–45.
135. Weijun X, Xiaojun S, Minzhi D, Xiaowen X, Changyong Z. Clinical observation of atomized inhalation of Tanreqing injection in treating acute exacerbation of chronic obstructive pulmonary disease. *J Em Trad Chin Med*. 2017;5(26):162–164.
136. Jiewu Y, Min Z. Application of Danhong injection in emergency treatment of patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. *J Em Trad Chin Med*. 2012;21(7):1150.
137. Ruifang Y, Xiue S, Caiyan W, Xiaofeng M. Clinical observation of Danhong injection in the treatment of 42 cases of acute exacerbation of chronic obstructive pulmonary disease in the elderly. *Health Vocational Educ*. 2010;28(5):139.
138. Weizhong Y, Lanke Z, Zhongtian D, Yuelian L, Yiyun L. Effect analysis of Tanreqing injection in adjuvant treatment of 120 elderly patients with AECOPD. *Guangxi Med J*. 2014;36(12):1804–1805.
139. Xiuhong Y. Tanreqing Injection in Adjuvant Treatment of 26 Cases of Acute COPD. *Shandong Med J*. 2006;46(14):39.
140. Ling Y, Xuchu H. Effect of Xuebijing injection on plasma D-dimer and fibrinogen in patients with AECOPD. *J Em Trad Chin Med*. 2010;19(10):1674–1675.
141. Shihua Y, Yabo Z, Jijun Y. Application Significance Reduning Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *J North Pharm*. 2016;13(6):18–19.
142. Libo Y. Tanreqing injection in treating 32 cases of acute exacerbation of chronic obstructive pulmonary. *Jiangxi J Trad Chin Med*. 2009;40(10):27–28.
143. Changxiu Y. Clinical study on the adjuvant treatment of chronic obstructive pulmonary disease with Shenmai injection. *Zhonghua Yangsheng Baojian*. 2020;39(1):40–42.

144. Chimei Z. Observation of curative effect of astragalus injection on acute exacerbation of chronic obstructive pulmonary disease. *Yunnan J Traditional Chin Med Materia Medica*. 2014;35(10):54.
145. Li Z. Efficacy of integrated traditional Chinese and western medicine in treating acute exacerbation of chronic obstructive pulmonary disease in the elderly. *Chin Foreign Med Res*. 2013;11(24):26–27.
146. Liyun Z, Lili L, Wei W. Clinical Observation on Atomized Zhichuanling Injection for the Treatment of 60 Cases with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *World Chin Med*. 2017;12(7):1562–1565.
147. Qiang Z. Clinical Analysis of Qingkailing Combined Medication Treatment of Elderly Patients with COPD Infection. *Chin J Basic Med Traditional Chin Med*. 2015;21(7):841–843.
148. Qiong Z. Randomized controlled study in parallel with acute exacerbation chronic obstructive pulmonary disease of Danhong injection combined with western medicine. *J Pract Traditional Chin Internal Med*. 2014;28(2):113–114.
149. Wenqian Z. Qingkailing aerosol inhalation treated 36 cases of acute exacerbation of chronic obstructive pulmonary disease. *Jilin Med J*. 2010;31(9):1215.
150. Xiaohua Z. Efficacy analysis of Honghua injection combined with routine treatment for 47 cases of chronic obstructive pulmonary disease in aggravation stage. *China Rural Health*. 2016;80(2):78–79.
151. Xin Z, Yan W, Aixiang G. Influence of Xiyanping injections therapy on inflammation factors and lung function of old patients with acute exacerbation chronic obstructive pulmonary disease. *Clin Med China*. 2014;30(9):932–935.
152. Ying Z, Tingqian L, Gang W, et al. Randomized Controlled Trial of Tanreqing Injection in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(Syndrome of Retention of Phlegm-Heat in the Lung). *Chin J Evid Based Med*. 2004;4(5):300–305.
153. Yuanhua Z, Yunfei G. Curative effect of Kudiezi injection on acute phase of chronic obstructive pulmonary disease. *Yunnan J Traditional Chin Med Materia Medica*. 2015;36(4):43–44.
154. Zhenhuan Z, Weili J, Yan J, Zhongguo S, Hai D. Clinical Observation of Shuanghuanglian Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *China Pharm*. 2016;27(29):4096–4098.
155. Yalil Z, Baoyon H. Effects of Shenfu injection on the patients with acute exacerbation of chronic obstruction pulmonary disease. *Inte J Geriatrics*. 2017;38(2):63–66.
156. Aizhu Z. Therapeutic effect of Xuesaitong injection on acute exacerbation of chronic obstructive pulmonary disease. *J Chin Pract Diagnosis Therapy*. 2013;27(7):696–698.
157. Jianguo Z. Clinical effect of Reduning injection on acute exacerbation of chronic obstructive pulmonary disease. *Pract J Cardiac Cerebral Pneumal Vasc Dis*. 2014;22(11):83–84.
158. Zhong Z, Chuanxiu W. Clinical observation of tanreqing injection in treatment of acute exacerbation of COPD. *J Em Trad Chin Med*. 2009;18(1):5–6.
159. Xiqing Z, Jianliang Z, Huimin S. Danhong injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease and its effect on hemorheology. *J Em Trad Chin Med*. 2010;19(2):197.

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>